<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Appl Clin Med Phys</journal-id><journal-id journal-id-type="iso-abbrev">J Appl Clin Med Phys</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1526-9914</journal-id><journal-id journal-id-type="publisher-id">ACM2</journal-id><journal-title-group><journal-title>Journal of Applied Clinical Medical Physics</journal-title></journal-title-group><issn pub-type="epub">1526-9914</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30636367</article-id><article-id pub-id-type="pmc">6370996</article-id><article-id pub-id-type="doi">10.1002/acm2.12528</article-id><article-id pub-id-type="publisher-id">ACM212528</article-id><article-categories><subj-group subj-group-type="JEL-classification"><subject>87.55.dk</subject></subj-group><subj-group subj-group-type="JEL-classification"><subject>87.55.tg</subject></subj-group><subj-group subj-group-type="overline"><subject>Radiation Oncology Physics</subject></subj-group><subj-group subj-group-type="heading"><subject>Radiation Oncology Physics</subject></subj-group></article-categories><title-group><article-title>Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geometrically driven <styled-content style="fixed-case">DVH</styled-content> prediction model</article-title><alt-title alt-title-type="left-running-head">NAKAMURA <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="acm212528-cr-0001" contrib-type="author" corresp="yes"><name><surname>Nakamura</surname><given-names>Akira</given-names></name><address><email>akiran@kuhp.kyoto-u.ac.jp</email><email>anakamura@mgh.harvard.edu</email></address><xref ref-type="aff" rid="acm212528-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="acm212528-cr-0002" contrib-type="author"><name><surname>Prichard</surname><given-names>Hugh A.</given-names></name><xref ref-type="aff" rid="acm212528-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="acm212528-cr-0003" contrib-type="author"><name><surname>Wo</surname><given-names>Jennifer Y.</given-names></name><xref ref-type="aff" rid="acm212528-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="acm212528-cr-0004" contrib-type="author"><name><surname>Wolfgang</surname><given-names>John A.</given-names></name><xref ref-type="aff" rid="acm212528-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="acm212528-cr-0005" contrib-type="author"><name><surname>Hong</surname><given-names>Theodore S.</given-names></name><xref ref-type="aff" rid="acm212528-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="acm212528-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Radiation Oncology</named-content>
<institution>Massachusetts General Hospital</institution>
<institution>Harvard Medical School</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Author to whom correspondence should be addressed. Akira Nakamura<break/>
E&#x02010;mails: <email>akiran@kuhp.kyoto-u.ac.jp</email>; <email>anakamura@mgh.harvard.edu</email>; Telephone: (617) 356&#x02010;7217<break/></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2019</year></pub-date><volume>20</volume><issue>2</issue><issue-id pub-id-type="doi">10.1002/acm2.2019.20.issue-2</issue-id><fpage>71</fpage><lpage>83</lpage><history><date date-type="received"><day>23</day><month>4</month><year>2018</year></date><date date-type="rev-recd"><day>05</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 American Association of Physicists in Medicine <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2019 The Authors. <italic>Journal of Applied Clinical Medical Physics</italic> published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ACM2-20-71.pdf"/><abstract id="acm212528-abs-0001"><title>Abstract</title><sec id="acm212528-sec-0001"><title>Purpose</title><p>We evaluate the feasibility of the elective nodal irradiation strategy in stereotactic body radiotherapy (<styled-content style="fixed-case">SBRT</styled-content>) for pancreatic cancer.</p></sec><sec id="acm212528-sec-0002"><title>Methods</title><p>Three simultaneous integrated boost (<styled-content style="fixed-case">SIB</styled-content>)&#x02010;<styled-content style="fixed-case">SBRT</styled-content> plans (Boost1, Boost2, and Boost3) were retrospectively generated for each of 20 different patients. Boost1 delivered 33 and 25&#x000a0;Gy to <styled-content style="fixed-case">PTV</styled-content>1 and <styled-content style="fixed-case">PTV</styled-content>2, respectively. Boost2 delivered 40, 33, and 25&#x000a0;Gy to boost<styled-content style="fixed-case">CTV</styled-content>,<styled-content style="fixed-case"> PTV</styled-content>1, and <styled-content style="fixed-case">PTV</styled-content>2, respectively. Boost3 delivered 33 and 25&#x000a0;Gy to <styled-content style="fixed-case">PTV</styled-content>1 and <styled-content style="fixed-case">PTV</styled-content>3, respectively. <styled-content style="fixed-case">PTV</styled-content>1 covered the initial standard <styled-content style="fixed-case">SBRT</styled-content> plan (InitPlan) gross tumor volume (<styled-content style="fixed-case">GTV</styled-content>). <styled-content style="fixed-case">PTV</styled-content>2 covered <styled-content style="fixed-case">CTV</styled-content>geom which was created by a 10&#x02010;mm expansion (15&#x000a0;mm posterior) of <styled-content style="fixed-case">GTV</styled-content>. <styled-content style="fixed-case">PTV</styled-content>3 covered <styled-content style="fixed-case">CTV</styled-content>prop which included elective nodal regions. The boost<styled-content style="fixed-case">CTV</styled-content> included <styled-content style="fixed-case">GTV</styled-content> as well as involved vasculature. The planning feasibility in each scenario and dose&#x02013;volume histograms (<styled-content style="fixed-case">DVH</styled-content>s) were analyzed and compared with the InitPlan (delivered 33&#x000a0;Gy only to <styled-content style="fixed-case">PTV</styled-content>1) by paired <italic>t</italic>&#x02010;test. Next, a novel <styled-content style="fixed-case">DVH</styled-content> prediction model was developed and its performance was evaluated according to the prediction accuracy (AC) of planning violations. Then, the model was used to simulate the impacts of <styled-content style="fixed-case">GTV</styled-content>&#x02010;to&#x02010;organs at risk (<styled-content style="fixed-case">OAR</styled-content>) distance and gastrointestinal (<styled-content style="fixed-case">GI</styled-content>) <styled-content style="fixed-case">OAR</styled-content> volume variations on planning feasibility.</p></sec><sec id="acm212528-sec-0003"><title>Results</title><p>Significant dose increases were observed in <styled-content style="fixed-case">GI</styled-content>&#x02010;<styled-content style="fixed-case">OAR</styled-content>s in <styled-content style="fixed-case">SIB</styled-content>&#x02010;<styled-content style="fixed-case">SBRT</styled-content> plans when compared with InitPlan. All dose constraints were met in 63% of cases in InitPlan, Boost1, and Boost2, whereas Boost3 developed <styled-content style="fixed-case">DVH</styled-content> violations in all cases. Utilizing previous patient anatomy, the novel <styled-content style="fixed-case">DVH</styled-content> prediction model achieved a high AC in the prediction of violations for <styled-content style="fixed-case">GI</styled-content>&#x02010;<styled-content style="fixed-case">OAR</styled-content>s; the positive predictive value, negative predictive value, and AC were 66%, 90%, and 84%, respectively. Experiments with the model demonstrated that the larger proximity volume of <styled-content style="fixed-case">GI</styled-content>&#x02010;<styled-content style="fixed-case">OAR</styled-content> at the shorter distance substantially impacted on planning violations.</p></sec><sec id="acm212528-sec-0004"><title>Conclusions</title><p>
<styled-content style="fixed-case">SIB</styled-content>&#x02010;<styled-content style="fixed-case">SBRT</styled-content> plan with geometrically defined prophylactic areas can be dosimetrically feasible, but including all nodal areas with 25&#x000a0;Gy in five fractions appears to be unrealistic.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="acm212528-kwd-0001">pancreatic cancer</kwd><kwd id="acm212528-kwd-0002">planning study</kwd><kwd id="acm212528-kwd-0003">prophylactic irradiation</kwd><kwd id="acm212528-kwd-0004"><styled-content style="fixed-case">SBRT</styled-content></kwd></kwd-group><counts><fig-count count="5"/><table-count count="5"/><page-count count="13"/><word-count count="10453"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>acm212528</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.5.8 mode:remove_FC converted:12.02.2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="acm212528-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Stereotactic body radiotherapy (SBRT) is increasingly being used for unresectable, locally advanced pancreatic cancer (LAPC) as well as in the neoadjuvant setting for borderline resectable diseases.<xref rid="acm212528-bib-0001" ref-type="ref">1</xref> SBRT delivers larger radiation doses in three to five fractions with more conformable dose distribution than conventional chemoradiation therapy (CRT).<xref rid="acm212528-bib-0002" ref-type="ref">2</xref> The small target volumes of pancreatic SBRT without covering any prophylactic nodal areas allow steeper dose gradients and a better sparing of abdominal organs at risk (OAR),<xref rid="acm212528-bib-0003" ref-type="ref">3</xref>, <xref rid="acm212528-bib-0004" ref-type="ref">4</xref>, <xref rid="acm212528-bib-0005" ref-type="ref">5</xref> thus potentially limiting the toxicity.</p><p>Data from multiple studies of neoadjuvant CRT highlight the prognostic importance of the margin status and residual nodal involvement in resected pancreatic cancer.<xref rid="acm212528-bib-0006" ref-type="ref">6</xref>, <xref rid="acm212528-bib-0007" ref-type="ref">7</xref>, <xref rid="acm212528-bib-0008" ref-type="ref">8</xref>, <xref rid="acm212528-bib-0009" ref-type="ref">9</xref>, <xref rid="acm212528-bib-0010" ref-type="ref">10</xref> To date, limited data have been available on these factors from patients who received SBRT and resection.<xref rid="acm212528-bib-0011" ref-type="ref">11</xref>, <xref rid="acm212528-bib-0012" ref-type="ref">12</xref>, <xref rid="acm212528-bib-0013" ref-type="ref">13</xref> Polistina et&#x000a0;al.<xref rid="acm212528-bib-0011" ref-type="ref">11</xref> reported that two patients underwent resection following neoadjuvant chemotherapy and SBRT, and both had at least two positive peripancreatic lymph nodes despite the negative margin and good local responses. Mellon et&#x000a0;al.<xref rid="acm212528-bib-0013" ref-type="ref">13</xref> reported that fewer positive lymph nodes were observed in the neoadjuvant SBRT group in comparison with patients who received upfront surgery (42.6% vs 60.6%). These results suggest that the neoadjuvant short&#x02010;course SBRT is a viable approach, although treatment effects on micrometastases to regional lymphatics were still unsatisfactory. Given the prognostic importance of resection margin status as well as lymph node positivity in pancreatic cancer, the prophylactic irradiation may improve outcomes of pancreatic SBRT, if it can be applied without increasing severe toxicities.</p><p>Previously, we conducted phase I studies of preoperative short&#x02010;course radiotherapy,<xref rid="acm212528-bib-0014" ref-type="ref">14</xref>, <xref rid="acm212528-bib-0015" ref-type="ref">15</xref> which included prophylactic nodal area irradiation, and we experienced unexpected intraoperative complications from photon therapy although its prescription dose was relatively modest (25&#x000a0;Gy in five fractions). Dosimetric analyses found that, compared with proton therapy, larger volumes of gastrointestinal (GI) OARs had been irradiated with low doses of photon therapy,<xref rid="acm212528-bib-0015" ref-type="ref">15</xref>, <xref rid="acm212528-bib-0016" ref-type="ref">16</xref> which were thought to lead to intraoperative complications.<xref rid="acm212528-bib-0017" ref-type="ref">17</xref> With growing evidences for the pancreatic SBRT dosimetry<xref rid="acm212528-bib-0003" ref-type="ref">3</xref>, <xref rid="acm212528-bib-0004" ref-type="ref">4</xref>, <xref rid="acm212528-bib-0005" ref-type="ref">5</xref> and recent clinical studies on the dose&#x02013;toxicity relationship,<xref rid="acm212528-bib-0018" ref-type="ref">18</xref>, <xref rid="acm212528-bib-0019" ref-type="ref">19</xref>, <xref rid="acm212528-bib-0020" ref-type="ref">20</xref> strict dose constraints on GI&#x02010;OARs have been accepted.<xref rid="acm212528-bib-0021" ref-type="ref">21</xref>, <xref rid="acm212528-bib-0022" ref-type="ref">22</xref> Achieving these constraints would be necessary to establish a safe SBRT, even with prophylactic area irradiation. In the meantime, impacts of patient anatomy on the planning feasibility have been reported.<xref rid="acm212528-bib-0003" ref-type="ref">3</xref>, <xref rid="acm212528-bib-0004" ref-type="ref">4</xref> Important questions for SBRT prophylactic area irradiation include how geometrical information relates to the planning feasibility as well as to what extent regions can be safely treated. Therefore, a fundamental study to evaluate its feasibility is needed before the introduction of this approach to the clinical setting.</p><p>The purpose of this study was twofold: to retrospectively generate the treatment plans of standard tumor&#x02010;only SBRT and of an alternative dose painting SBRT strategy to cover relevant nodal volume, vascular involvement, or prophylactic areas. Then, we evaluated the ratio of successful treatment planning in each scenario. Next, we developed a new geometry&#x02010;driven dose&#x02013;volume histogram (DVH) prediction model to evaluate the geometry&#x02013;dosimetry relationship and elucidate what factors were crucial for the failure planning to achieve dose constraints in SIB&#x02010;SBRT for patients with pancreatic cancer. Figure&#x000a0;<xref rid="acm212528-fig-0001" ref-type="fig">1</xref> outlines a flow diagram of the dataset and the SBRT planning, DVH prediction models, and experiments introduced in the following sections.</p><fig fig-type="Figure" xml:lang="en" id="acm212528-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram of study design.</p></caption><graphic id="nlm-graphic-1" xlink:href="ACM2-20-71-g001"/></fig></sec><sec id="acm212528-sec-0006"><label>2</label><title>MATERIALS AND METHODS</title><sec id="acm212528-sec-0007"><label>2.A</label><title>Patient and treatment planning</title><sec id="acm212528-sec-0008"><label>2.A.1</label><title>Patient selection and target definition</title><p>This was a single&#x02010;institution retrospective planning study, approved by the Institutional Review Board. A total of 20 patients with pancreatic cancer who received radiotherapy were selected (Table&#x000a0;<xref rid="acm212528-tbl-0001" ref-type="table">1</xref>). The planning computed tomography (CT) images and digital image communications in medicine&#x02010;radiation therapy (DICOM&#x02010;RT) structure set were deidentified and exported to the treatment planning system. All simulation CTs were performed with a contrast&#x02010;enhanced agent without oral contrast. Patients were in the prone position with both arms raised overhead.</p><table-wrap id="acm212528-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient characteristics and tumor size</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Pt.</th><th align="left" valign="top" rowspan="1" colspan="1">Gender</th><th align="left" valign="top" rowspan="1" colspan="1">Age</th><th align="left" valign="top" rowspan="1" colspan="1">Tumor</th><th align="center" valign="top" rowspan="1" colspan="1">GTV</th><th align="center" valign="top" rowspan="1" colspan="1">CTVgeom</th><th align="center" valign="top" rowspan="1" colspan="1">CTVprop</th><th align="center" valign="top" rowspan="1" colspan="1">PTV1</th><th align="center" valign="top" rowspan="1" colspan="1">PTV2</th><th align="center" valign="top" rowspan="1" colspan="1">PTV3</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">Body</td><td align="char" char=" " rowspan="1" colspan="1">5</td><td align="char" char=" " rowspan="1" colspan="1">47</td><td align="char" char=" " rowspan="1" colspan="1">349</td><td align="char" char=" " rowspan="1" colspan="1">10</td><td align="char" char=" " rowspan="1" colspan="1">68</td><td align="char" char=" " rowspan="1" colspan="1">428</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">13</td><td align="char" char=" " rowspan="1" colspan="1">70</td><td align="char" char=" " rowspan="1" colspan="1">259</td><td align="char" char=" " rowspan="1" colspan="1">25</td><td align="char" char=" " rowspan="1" colspan="1">98</td><td align="char" char=" " rowspan="1" colspan="1">336</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">Tail</td><td align="char" char=" " rowspan="1" colspan="1">29</td><td align="char" char=" " rowspan="1" colspan="1">144</td><td align="char" char=" " rowspan="1" colspan="1">91</td><td align="char" char=" " rowspan="1" colspan="1">57</td><td align="char" char=" " rowspan="1" colspan="1">196</td><td align="char" char=" " rowspan="1" colspan="1">143</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">101</td><td align="char" char=" " rowspan="1" colspan="1">303</td><td align="char" char=" " rowspan="1" colspan="1">227</td><td align="char" char=" " rowspan="1" colspan="1">136</td><td align="char" char=" " rowspan="1" colspan="1">431</td><td align="char" char=" " rowspan="1" colspan="1">315</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">89</td><td align="char" char=" " rowspan="1" colspan="1">278</td><td align="char" char=" " rowspan="1" colspan="1">271</td><td align="char" char=" " rowspan="1" colspan="1">120</td><td align="char" char=" " rowspan="1" colspan="1">377</td><td align="char" char=" " rowspan="1" colspan="1">363</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">61</td><td align="char" char=" " rowspan="1" colspan="1">215</td><td align="char" char=" " rowspan="1" colspan="1">441</td><td align="char" char=" " rowspan="1" colspan="1">88</td><td align="char" char=" " rowspan="1" colspan="1">286</td><td align="char" char=" " rowspan="1" colspan="1">553</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">33</td><td align="char" char=" " rowspan="1" colspan="1">122</td><td align="char" char=" " rowspan="1" colspan="1">424</td><td align="char" char=" " rowspan="1" colspan="1">47</td><td align="char" char=" " rowspan="1" colspan="1">166</td><td align="char" char=" " rowspan="1" colspan="1">545</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">56</td><td align="char" char=" " rowspan="1" colspan="1">210</td><td align="char" char=" " rowspan="1" colspan="1">401</td><td align="char" char=" " rowspan="1" colspan="1">83</td><td align="char" char=" " rowspan="1" colspan="1">284</td><td align="char" char=" " rowspan="1" colspan="1">469</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">Body</td><td align="char" char=" " rowspan="1" colspan="1">70</td><td align="char" char=" " rowspan="1" colspan="1">212</td><td align="char" char=" " rowspan="1" colspan="1">427</td><td align="char" char=" " rowspan="1" colspan="1">107</td><td align="char" char=" " rowspan="1" colspan="1">274</td><td align="char" char=" " rowspan="1" colspan="1">544</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">26</td><td align="char" char=" " rowspan="1" colspan="1">111</td><td align="char" char=" " rowspan="1" colspan="1">221</td><td align="char" char=" " rowspan="1" colspan="1">39</td><td align="char" char=" " rowspan="1" colspan="1">154</td><td align="char" char=" " rowspan="1" colspan="1">290</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">8</td><td align="char" char=" " rowspan="1" colspan="1">58</td><td align="char" char=" " rowspan="1" colspan="1">140</td><td align="char" char=" " rowspan="1" colspan="1">17</td><td align="char" char=" " rowspan="1" colspan="1">83</td><td align="char" char=" " rowspan="1" colspan="1">195</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">39</td><td align="char" char=" " rowspan="1" colspan="1">188</td><td align="char" char=" " rowspan="1" colspan="1">368</td><td align="char" char=" " rowspan="1" colspan="1">73</td><td align="char" char=" " rowspan="1" colspan="1">254</td><td align="char" char=" " rowspan="1" colspan="1">473</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">9</td><td align="char" char=" " rowspan="1" colspan="1">55</td><td align="char" char=" " rowspan="1" colspan="1">304</td><td align="char" char=" " rowspan="1" colspan="1">18</td><td align="char" char=" " rowspan="1" colspan="1">78</td><td align="char" char=" " rowspan="1" colspan="1">404</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">57</td><td align="char" char=" " rowspan="1" colspan="1">218</td><td align="char" char=" " rowspan="1" colspan="1">339</td><td align="char" char=" " rowspan="1" colspan="1">95</td><td align="char" char=" " rowspan="1" colspan="1">282</td><td align="char" char=" " rowspan="1" colspan="1">452</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">4</td><td align="char" char=" " rowspan="1" colspan="1">40</td><td align="char" char=" " rowspan="1" colspan="1">75</td><td align="char" char=" " rowspan="1" colspan="1">11</td><td align="char" char=" " rowspan="1" colspan="1">59</td><td align="char" char=" " rowspan="1" colspan="1">112</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">35</td><td align="char" char=" " rowspan="1" colspan="1">167</td><td align="char" char=" " rowspan="1" colspan="1">259</td><td align="char" char=" " rowspan="1" colspan="1">66</td><td align="char" char=" " rowspan="1" colspan="1">217</td><td align="char" char=" " rowspan="1" colspan="1">346</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">16</td><td align="char" char=" " rowspan="1" colspan="1">94</td><td align="char" char=" " rowspan="1" colspan="1">349</td><td align="char" char=" " rowspan="1" colspan="1">33</td><td align="char" char=" " rowspan="1" colspan="1">129</td><td align="char" char=" " rowspan="1" colspan="1">462</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">24</td><td align="char" char=" " rowspan="1" colspan="1">117</td><td align="char" char=" " rowspan="1" colspan="1">235</td><td align="char" char=" " rowspan="1" colspan="1">45</td><td align="char" char=" " rowspan="1" colspan="1">157</td><td align="char" char=" " rowspan="1" colspan="1">395</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1">Body</td><td align="char" char=" " rowspan="1" colspan="1">38</td><td align="char" char=" " rowspan="1" colspan="1">178</td><td align="char" char=" " rowspan="1" colspan="1">336</td><td align="char" char=" " rowspan="1" colspan="1">71</td><td align="char" char=" " rowspan="1" colspan="1">237</td><td align="char" char=" " rowspan="1" colspan="1">436</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">Head</td><td align="char" char=" " rowspan="1" colspan="1">16</td><td align="char" char=" " rowspan="1" colspan="1">101</td><td align="char" char=" " rowspan="1" colspan="1">241</td><td align="char" char=" " rowspan="1" colspan="1">34</td><td align="char" char=" " rowspan="1" colspan="1">140</td><td align="char" char=" " rowspan="1" colspan="1">327</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">36</td><td align="char" char=" " rowspan="1" colspan="1">146</td><td align="char" char=" " rowspan="1" colspan="1">288</td><td align="char" char=" " rowspan="1" colspan="1">59</td><td align="char" char=" " rowspan="1" colspan="1">199</td><td align="char" char=" " rowspan="1" colspan="1">379</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">31</td><td align="char" char=" " rowspan="1" colspan="1">133</td><td align="char" char=" " rowspan="1" colspan="1">288</td><td align="char" char=" " rowspan="1" colspan="1">52</td><td align="char" char=" " rowspan="1" colspan="1">181</td><td align="char" char=" " rowspan="1" colspan="1">400</td></tr><tr><td align="left" rowspan="1" colspan="1">Min</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">4</td><td align="char" char=" " rowspan="1" colspan="1">40</td><td align="char" char=" " rowspan="1" colspan="1">75</td><td align="char" char=" " rowspan="1" colspan="1">10</td><td align="char" char=" " rowspan="1" colspan="1">59</td><td align="char" char=" " rowspan="1" colspan="1">112</td></tr><tr><td align="left" rowspan="1" colspan="1">Max</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">101</td><td align="char" char=" " rowspan="1" colspan="1">303</td><td align="char" char=" " rowspan="1" colspan="1">441</td><td align="char" char=" " rowspan="1" colspan="1">136</td><td align="char" char=" " rowspan="1" colspan="1">431</td><td align="char" char=" " rowspan="1" colspan="1">553</td></tr></tbody></table><table-wrap-foot><fn id="acm212528-note-0001"><p>Structure volume are shown in mL.</p></fn><fn id="acm212528-note-0002"><p>Pt.&#x000a0;=&#x000a0;patient number; M&#x000a0;=&#x000a0;male; F&#x000a0;=&#x000a0;female; GTV&#x000a0;=&#x000a0;gross tumor volume; CTV&#x000a0;=&#x000a0;clinical target volume; CTVgeom&#x000a0;=&#x000a0;geometrical CTV; CTVprop&#x000a0;=&#x000a0;prophylactic CTV; PTV&#x000a0;=&#x000a0;planning target volume.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The gross tumor volume (GTV) was delineated by treating radiation oncologists, and OAR including the stomach, duodenum, bowel, kidneys, liver, and spinal cord were delineated and used for the plan optimization. Three clinical target volumes (CTVs) were defined; first, a geometrical CTV (CTVgeom) was created with a 10&#x02010;mm isotropic expansion (15&#x000a0;mm posterior) of the GTV. Second, boostCTV was defined as the target volume of GTV in continuity with the involved vasculature, as well as the retroperitoneum posterior to the SMV/SMA or celiac axis. In addition, a part of boostCTV which was within 1&#x000a0;cm from the surface of the GI&#x02010;OARs was omitted. Third, prophylactic CTV (CTVprop) was defined as GTV plus a prophylactic lymph node area, namely peripancreas, retropancreas, portahepatis, and para&#x02010;aorta, according to the tumor location. These CTVs were selected because these regions are clinically relevant for the micrometastasis to regional lymphatics or the microscopic extension from primary tumor.<xref rid="acm212528-bib-0006" ref-type="ref">6</xref>, <xref rid="acm212528-bib-0007" ref-type="ref">7</xref>, <xref rid="acm212528-bib-0008" ref-type="ref">8</xref>, <xref rid="acm212528-bib-0009" ref-type="ref">9</xref>, <xref rid="acm212528-bib-0010" ref-type="ref">10</xref> Also, recent practical guidelines recommend CTV margin of 5&#x02013;15&#x000a0;mm expansion from GTV.<xref rid="acm212528-bib-0023" ref-type="ref">23</xref> In support of this, we previously reported the tumor size discrepancy between the CT and the pathological sample and suggested a GTV&#x02010;to&#x02010;CTV margin formula based on a diameter of tumor.<xref rid="acm212528-bib-0024" ref-type="ref">24</xref> With these facts, we performed preliminary experimental planning using several margin sizes and determined the margins for CTVgeom. Figure&#x000a0;<xref rid="acm212528-fig-0002" ref-type="fig">2</xref> illustrates these definitions of target structures.</p><fig fig-type="Figure" xml:lang="en" id="acm212528-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Definitions of target volumes for <styled-content style="fixed-case">SBRT</styled-content> and <styled-content style="fixed-case">SIB</styled-content>&#x02010;<styled-content style="fixed-case">SBRT</styled-content> plans. Red&#x000a0;=&#x000a0;gross tumor volume (<styled-content style="fixed-case">GTV</styled-content>), yellow&#x000a0;=&#x000a0;geometrically defined clinical target volume (<styled-content style="fixed-case">CTV</styled-content>geom) which are created by expanding 10&#x02013;15&#x000a0;mm from <styled-content style="fixed-case">GTV</styled-content>, orange&#x000a0;=&#x000a0;clinical defined prophylactic clinical target volume (<styled-content style="fixed-case">CTV</styled-content>prop), and purple&#x000a0;=&#x000a0;boost <styled-content style="fixed-case">CTV</styled-content> for <styled-content style="fixed-case">GTV</styled-content>, as well as the involvement of vasculature. Pink&#x000a0;=&#x000a0;planning target volume 1 (<styled-content style="fixed-case">PTV</styled-content>1) which is created by expanding 3&#x000a0;mm from <styled-content style="fixed-case">GTV</styled-content>, brown&#x000a0;=&#x000a0;<styled-content style="fixed-case">PTV</styled-content>2 which is created by expanding 3&#x000a0;mm from <styled-content style="fixed-case">CTV</styled-content>geom, and light brown&#x000a0;=&#x000a0;<styled-content style="fixed-case">PTV</styled-content>3 which is created by expanding 3&#x000a0;mm from <styled-content style="fixed-case">CTV</styled-content>prop. <styled-content style="fixed-case">PTV</styled-content>1, <styled-content style="fixed-case">PTV</styled-content>2, <styled-content style="fixed-case">PTV</styled-content>3, and boost<styled-content style="fixed-case">CTV</styled-content> receive 33, 25, 25, and 40&#x000a0;Gy, respectively. Both b and c include the same <styled-content style="fixed-case">CTV</styled-content>geom while the boost<styled-content style="fixed-case">CTV</styled-content> is also created in c. These target volumes are used for (a) InitPlan, (b) Boost1, (c) Boost2, and (d) Boost3.</p></caption><graphic id="nlm-graphic-3" xlink:href="ACM2-20-71-g002"/></fig><p>Three definitions of planning target volume (PTV) were created; PTV1, PTV2, and PTV3 were defined as a 3&#x02010;mm isotropic expansion of the GTV, CTVgeom, and CTVprop, respectively. Of note, the overlapping volumes between PTVs and critical normal structures, including the stomach, duodenum, and small bowels, were subtracted from PTV1, PTV2, and PTV3. Table&#x000a0;<xref rid="acm212528-tbl-0002" ref-type="table">2</xref> summarizes these definitions and differences of the structures in the plans described in the following section.</p><table-wrap id="acm212528-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Definitions of target structures in SBRT and SIB&#x02010;SBRT plans</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Structure CTVgeom</th><th align="left" valign="top" rowspan="1" colspan="1">boostCTV</th><th align="left" valign="top" rowspan="1" colspan="1">CTVprop</th><th align="left" valign="top" rowspan="1" colspan="1">PTV1<xref ref-type="fn" rid="acm212528-note-0103">b</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">PTV2</th><th align="left" valign="top" rowspan="1" colspan="1">PTV3</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Definitions</td><td align="left" rowspan="1" colspan="1">GTV + 10&#x02010;mm (15&#x02010;mm posterior) expansion</td><td align="left" rowspan="1" colspan="1">GTV + involved vasculature + retroperitoneum posterior to SMV/SMA or celiac axis</td><td align="left" rowspan="1" colspan="1">GTV + elective nodal regions (peripancreas, retropancreas, porta&#x02010;hepatis, para&#x02010;aorta) </td><td align="left" rowspan="1" colspan="1">GTV + 3&#x02010;mm</td><td align="left" rowspan="1" colspan="1">CTVgeom + 3&#x02010;mm</td><td align="left" rowspan="1" colspan="1">CTVprop+ 3&#x02010;mm</td></tr><tr><td align="left" rowspan="1" colspan="1">Prescription <xref ref-type="fn" rid="acm212528-note-0102">a</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> InitPlan</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<underline underline-style="single"><bold>33 Gy</bold></underline>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Boost1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<underline underline-style="single"><bold>33 Gy</bold></underline>
</td><td align="left" rowspan="1" colspan="1">25 Gy</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Boost2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<underline underline-style="single"><bold>40 Gy</bold></underline>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">33 Gy</td><td align="left" rowspan="1" colspan="1">25 Gy</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"> Boost3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<underline underline-style="single"><bold>33 Gy</bold></underline>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25 Gy</td></tr></tbody></table><table-wrap-foot><fn id="acm212528-note-0101"><p>Abbreviations: GTV, gross tumor volume; CTV, clinical target volume; CTVgeom, geometrical CTV; CTVprop, prophylactic CTV; PTVx, planning target volume 1, 2, or 3.</p></fn><fn id="acm212528-note-0102"><label>a</label><p>Prescription doses in SBRT plan (InitPlan) or SIB&#x02010;SBRT plans (Boost1, Boost2, or Boost3) are shown. Each prescription dose is specified to D95 of the target structure(s), and the most prioritized structure in each plan was shown as bold underline.</p></fn><fn id="acm212528-note-0103"><label>b</label><p>The overlapping volumes between PTVx and critical normal structures were subtracted from PTVx.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="acm212528-sec-0009"><label>2.A.2</label><title>Treatment planning and Intensity&#x02010;modulated radiation therapy (IMRT) optimization</title><p>The IMRT treatment planning was performed on the RayStation (version 4.034, RaySearch, Stockholm, Sweden). Seven to nine coplanar or noncoplanar 6&#x02010;MV photon beams were used. Four concepts of SBRT plans for each patient were generated; for the standard SBRT plan (InitPlan), the prescription dose of 33&#x000a0;Gy was specified to D95 (the dose that covers 95% of the structure) of PTV1. For the first SIB plan (Boost1), 33 and 25&#x000a0;Gy were specified to D95 of PTV1 and PTV2, respectively. For the second SIB plan (Boost2), 40, 33, and 25&#x000a0;Gy were specified to D95 of boostCTV, PTV1 and PTV2, respectively, and boostCTV was more prioritized than D95 of PTV1. For the third SIB plan (Boost3), 33 and 25&#x000a0;Gy were specified to D95 of PTV1 and PTV3, respectively. The dose constraints for OARs were as follows: V12 (volume receiving&#x000a0;&#x02265;&#x000a0;12&#x000a0;Gy) of combined kidney less than or equal to 75%; the D50 of liver less than or equal to 12&#x000a0;Gy; the V23 to spinal cord less than 0.35&#x000a0;mL; the D9mL, D3mL, and D1mL of the GI&#x02010;OARs (stomach, duodenum, or bowel) less than or equal to 15&#x000a0;Gy, less than or equal to 20&#x000a0;Gy, and less than or equal to 33&#x000a0;Gy, respectively. We referred to the previous studies for these OAR constraints.<xref rid="acm212528-bib-0021" ref-type="ref">21</xref>, <xref rid="acm212528-bib-0022" ref-type="ref">22</xref> The calculation algorithm was Collapsed Cone v 2.3, and the calculation grid sizes were 0.2, 0.2, and 0.25&#x000a0;cm in left&#x02013;right, anterior&#x02013;posterior, and superior&#x02013;inferior directions, respectively.</p><p>The following factors were evaluated. The target coverage and the dose to OARs in four SBRT plans (InitPlan, Boost1, Boost2, and Boost3), and the number of cases with one or more violation were evaluated. The statistical significance in the difference in OAR doses between InitPlan vs SIB&#x02010;SBRT plans were tested by a paired <italic>t</italic>&#x02010;test.</p></sec></sec><sec id="acm212528-sec-0010"><label>2.B</label><title>Geometry&#x02010;driven DVH prediction model</title><sec id="acm212528-sec-0011"><label>2.B.1</label><title>Framework of the predicting DVHs</title><p>The minimal Euclidean distance from each OAR voxel to the boundary of a target structure was calculated, and the voxels were sorted into bins based on their distance to a target volume (Fig.&#x000a0;<xref rid="acm212528-fig-0003" ref-type="fig">3</xref>).<xref rid="acm212528-bib-0025" ref-type="ref">25</xref>, <xref rid="acm212528-bib-0026" ref-type="ref">26</xref>, <xref rid="acm212528-bib-0027" ref-type="ref">27</xref>, <xref rid="acm212528-bib-0028" ref-type="ref">28</xref> Here, we regarded the outermost target structure (i.e., PTV1 for InitPlan, PTV2 for Boost1 or Boost2, and PTV3 for Boost3) as the target volume. Then, we obtained a histogram of doses received by voxels (dose&#x02013;frequency histogram) at the same distance bin. The dose to each voxel was normalized by dividing by the prescription dose to the outermost target. Based on a preliminary result, the width of a distance bin was set to 0.5&#x000a0;mm with a range between &#x02212;10&#x000a0;mm and 150&#x000a0;mm. Then, all dose&#x02013;frequency histograms at the same distance bin from the training cohorts were combined.</p><fig fig-type="Figure" xml:lang="en" id="acm212528-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Framework of geometry&#x02010;driven dose&#x02013;volume histogram prediction model. (a), (b) For each voxel of <styled-content style="fixed-case">OAR</styled-content>s, the minimum distance from <styled-content style="fixed-case">PTV</styled-content> was calculated. Based on this distance, the voxels are sorted into different groups. The dose to voxels are acquired and combined to create dose&#x02013;frequency histograms, such as (1), (2), and (3). In the models with &#x0201c;separate <styled-content style="fixed-case">OAR</styled-content>s,&#x0201d; the voxels within the infield and outfield spaces are regarded as different groups. (c) Each dose&#x02013;frequency histogram contains the voxels and their doses at the same distant bins. These dose&#x02013;frequency histograms were used to predict the dose&#x02010;to&#x02010;voxels at a certain distance for a new patient, by applying a median dose or a distribution of them.</p></caption><graphic id="nlm-graphic-5" xlink:href="ACM2-20-71-g003"/></fig><p>To approximate the dose distribution of each distance bin and apply doses to each voxel of an OAR in a new patient, two approaches were tested. First, the single median value of a dose&#x02013;frequency histogram was used to represent a dose at a distance bin, and was applied to each voxel of an OAR of a new patient, as tested in a previous study for liver SBRT.<xref rid="acm212528-bib-0026" ref-type="ref">26</xref> Second, the distribution of dose&#x02013;frequency histogram was directly applied to represent the distribution of those in voxels at the corresponding distance bin of a new OAR, to keep the characteristics of dose&#x02013;frequency histograms from training cohorts. In addition, we tested the performance of dividing OAR voxels into separate volumes and obtaining two dose histograms: the dose histograms of voxels that are inside the treatment fields (infield) and those that are outside the treatment fields (outfield), as described previously.<xref rid="acm212528-bib-0025" ref-type="ref">25</xref>, <xref rid="acm212528-bib-0027" ref-type="ref">27</xref> The current study included both coplanar and noncoplanar beams (within &#x000b1;30&#x000b0; of the axial plane), so that outfield regions became a double conical region in three&#x02010;dimensional space (Fig.&#x000a0;<xref rid="acm212528-fig-0003" ref-type="fig">3</xref>). We tested three margin sizes (0, 5, and 10&#x000a0;mm) for the interval between the apex of each cone and the most superior/inferior aspects of the target surface.</p></sec><sec id="acm212528-sec-0012"><label>2.B.2</label><title>Evaluation and model validation experiments</title><p>First, we created the models using data from all 20 patients and predicted their DVHs. The performance of each model was evaluated by the mean and the standard deviation (SD) of the sum of residuals (SR) in each model.</p><p>
<disp-formula id="acm212528-disp-0001"><mml:math id="nlm-math-1"><mml:mrow><mml:mi>S</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#x0221e;</mml:mi></mml:munderover><mml:mfenced close=")" open="(" separators=""><mml:mi>D</mml:mi><mml:mi>V</mml:mi><mml:mi>H</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>D</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mi>D</mml:mi><mml:mi>V</mml:mi><mml:mi>H</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>D</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mfenced><mml:mo>&#x000b7;</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>D</mml:mi></mml:mrow></mml:math></disp-formula>
</p><p>To capture the essential behavior of dose histograms in the training cohort, the absolute mean SR should be much less than that of the SD of SR.<xref rid="acm212528-bib-0025" ref-type="ref">25</xref> Next, the performance of models for the validation cohort was evaluated multiple times (25 in this study) in a twofold cross&#x02010;validation test (i.e., double cross&#x02010;validation test); we separated the cohorts into two groups that randomly included 10 patients each, and we used one group as a training cohort to create a prediction model and the other group as a validation cohort. Then, the prediction errors were assessed with the mean and SDs of SR and the sum of squared residuals (RSS).</p><p>
<disp-formula id="acm212528-disp-0002"><mml:math id="nlm-math-2"><mml:mrow><mml:mi>R</mml:mi><mml:mi>S</mml:mi><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mi>&#x0221e;</mml:mi></mml:munderover><mml:msup><mml:mfenced close=")" open="(" separators=""><mml:mo stretchy="false">(</mml:mo><mml:mi>D</mml:mi><mml:mi>V</mml:mi><mml:mi>H</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>D</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mi>D</mml:mi><mml:mi>V</mml:mi><mml:mi>H</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>D</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x000b7;</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>D</mml:mi></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></disp-formula>
</p><p>Because three DVH metrics (D1mL, D3mL, and D9mL) of GI&#x02010;OARs are important factors for the plan validity, we evaluated the accuracy (AC) in predicting these metrics with the following factors: the absolute difference in volume, the positive predictive value (PPV), the negative predictive values (NPV), and the AC for predicting the violation. AC is defined as the ratio of true positives and true negatives to total predictions. If the model properly predicts that the critical DVHs are violated in validation cases, PPV should become high; and if the model properly predicts that the critical DVHs are not violated, NPV should become high.</p></sec></sec><sec id="acm212528-sec-0013"><label>2.C</label><title>Model&#x02010;based experiments</title><sec id="acm212528-sec-0014"><label>2.C.1</label><title>Required distance to keep the prediction performance of the model</title><p>We expected that the dose histograms from the proximal part of an OAR are more related to the prediction of DVHs. To estimate the impact of the distance&#x02010;to&#x02010;target on the performance of DVH prediction, we limited the distance&#x02010;to&#x02010;target and simulated changing it from 5 to 50&#x000a0;mm, within which we could only use the dose&#x02013;frequency histograms to predict DVHs. The model performance was assessed by the RSS.</p></sec><sec id="acm212528-sec-0015"><label>2.C.2</label><title>Simulations to assess the impact of proximity volumes of OARs on plan validity</title><p>By using our model, we assessed the impact of proximity volumes of GI&#x02010;OARs on the ratio of valid plans, which met&#x000a0;all dose constraints. We simulated changing volumes of virtual GI&#x02010;OARs from 5 to 50&#x000a0;mL, which were located randomly according to a normal (Gauss) distribution with a mean of a certain distance&#x02010;to&#x02010;target. Because the presented model does not include GTV parameters, simulations on GTV parameters are not performed. Then, we predicted the DVHs with the prediction model and assessed the ratio of valid SBRT plans. The distance&#x02010;to&#x02010;target was selected as 0&#x02013;5&#x000a0;mm to 0&#x02013;60&#x000a0;mm with an interval of 5&#x000a0;mm, and the number of simulations was 250.</p></sec></sec></sec><sec id="acm212528-sec-0016"><label>3</label><title>RESULTS</title><sec id="acm212528-sec-0017"><label>3.A</label><title>DVH analysis for four SBRT plans</title><p>The mean PTV values are 59, 199, and 379 for PTV1, PTV2, and PTV3, respectively. Among 20 patients, 2 patients (cases #4 and #15) did not have a duodenum volume because of a prior surgical intervention. The results of DVH analyses are shown in Table&#x000a0;<xref rid="acm212528-tbl-0003" ref-type="table">3</xref>. The target coverage was satisfied in all SBRT and SIB&#x02010;SBRT plans, but the doses to PTV2 or PTV3 slightly deviated from 25&#x000a0;Gy in three SIB&#x02010;SBRT plans because the prescription dose of 33&#x000a0;Gy to D95 of PTV1 (or 40&#x000a0;Gy to boostCTV in the plan Boost2) was prioritized, and we allowed the relaxed dose coverages for PTV2 or PTV3. Although PTV3 was not optimized to receive 25&#x000a0;Gy, the median dose (D50) to PTV3 in Boost1 or Boost2 was 23 or 25&#x000a0;Gy, respectively, which may partly satisfy the purpose of covering the elective nodal areas. The dose to CTVs were often modest when compared with dose coverages to the corresponding PTVs because CTVs had overlaps with GI&#x02010;OARs while the overlaps between PTVs and GI&#x02010;OARs were subtracted from PTVs. An example dose distribution of four SBRT plans are shown in Supporting Information Fig.&#x000a0;<xref rid="acm212528-sup-0001" ref-type="supplementary-material">S1</xref>. Also, example DVHs from InitPlan and Boost3 are shown in Supporting Information Fig.&#x000a0;<xref rid="acm212528-sup-0002" ref-type="supplementary-material">S2</xref>.</p><table-wrap id="acm212528-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Summary of DVHs in SBRT and SIB&#x02010;SBRT plans</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Structure</th><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Constraint</th><th align="left" valign="top" rowspan="1" colspan="1">Plans InitPlan</th><th align="left" valign="top" rowspan="1" colspan="1">Boost1</th><th align="center" valign="top" rowspan="1" colspan="1">
<xref ref-type="fn" rid="acm212528-note-0800">&#x02020;</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Boost2</th><th align="center" valign="top" rowspan="1" colspan="1">
<xref ref-type="fn" rid="acm212528-note-0800">&#x02020;</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Boost3</th><th align="center" valign="top" rowspan="1" colspan="1">
<xref ref-type="fn" rid="acm212528-note-0800">&#x02020;</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">GTV</td><td align="left" rowspan="1" colspan="1">D95% [%]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
100.4 (1.6)<break/>
100.7 [94, 103]
</td><td align="left" rowspan="1" colspan="1">
98.2 (7.7)<break/>
101.5 [86, 103]
</td><td align="char" char="." rowspan="1" colspan="1">0.042</td><td align="left" rowspan="1" colspan="1">
105.3 (16.8)<break/>
109 [84, 121]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
99.2 (4.3)<break/>
100.4 [89, 104]
</td><td align="char" char="." rowspan="1" colspan="1">0.031</td></tr><tr><td align="left" rowspan="1" colspan="1">CTVgeom</td><td align="left" rowspan="1" colspan="1">D95% [Gy] </td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
18.2 (2.1)<break/>
18 [15, 22]
</td><td align="left" rowspan="1" colspan="1">
22.1 (5.3)<break/>
23.7 [13, 28]
</td><td align="char" char="." rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">
22.2 (6)<break/>
23.3 [12, 35]
</td><td align="char" char="." rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">
22.8 (4)<break/>
21.2 [18, 31]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">CTVprop</td><td align="left" rowspan="1" colspan="1">D95% [Gy] </td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
3.7 (4.6)<break/>
1.6 [0, 18]
</td><td align="left" rowspan="1" colspan="1">
6.9 (7.3)<break/>
3 [0, 25]
</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">
7.6 (8)<break/>
3 [0, 25]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
22.8 (5.2)<break/>
23.9 [11, 33]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">boostCTV</td><td align="left" rowspan="1" colspan="1">D95% [Gy] </td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
28 (7.9)<break/>
32.2 [4, 34]
</td><td align="left" rowspan="1" colspan="1">
30.7 (4.6)<break/>
32.1 [13, 34]
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
40 (0)<break/>
40 [40, 40]
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
31.8 (1.9)<break/>
32.6 [28, 34]
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PTV1</td><td align="left" rowspan="1" colspan="1">D95% [%]</td><td align="left" rowspan="1" colspan="1">=100% <xref ref-type="fn" rid="acm212528-note-0700">*</xref>
</td><td align="left" rowspan="1" colspan="1">
100.0 (0)<break/>
100 [100, 100]
</td><td align="left" rowspan="1" colspan="1">
100 (0)<break/>
100 [100, 100]
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
107 (5.6)<break/>
106.2 [100, 121]
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
100 (0)<break/>
100 [100, 100]
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PTV2</td><td align="left" rowspan="1" colspan="1">D95% [Gy] </td><td align="left" rowspan="1" colspan="1">=25 Gy a</td><td align="left" rowspan="1" colspan="1">
13.6 (1.9)<break/>
13.7 [10, 17]
</td><td align="left" rowspan="1" colspan="1">
26 (0.6)<break/>
26 [25, 27]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
26.5 (1.3)<break/>
26.4 [25, 31]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
24.2 (3)<break/>
24.5 [19, 31]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D50% [Gy] </td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
27 (1.8)<break/>
26.7 [23, 30]
</td><td align="left" rowspan="1" colspan="1">
30 (1.1)<break/>
29.8 [29, 32]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
33.4 (1.6)<break/>
33.4 [31, 38]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
30.2 (1.8)<break/>
29.8 [28, 34]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">PTV3</td><td align="left" rowspan="1" colspan="1">D95% [Gy] </td><td align="left" rowspan="1" colspan="1">=25 Gy a</td><td align="left" rowspan="1" colspan="1">
2.8 (3.6)<break/>
1.2 [0, 14]
</td><td align="left" rowspan="1" colspan="1">
5.6 (6.2)<break/>
2.2 [0, 21]
</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">
6.2 (6.9)<break/>
2.3 [0, 24]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
25.8 (1.8)<break/>
25.5 [24, 33]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D50% [Gy] </td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
16.1 (8.2)<break/>
16.2 [1, 33]
</td><td align="left" rowspan="1" colspan="1">
23 (7.1)<break/>
25.3 [5, 33]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
25.4 (7.7)<break/>
26.7 [8, 40]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
29.1 (2.2)<break/>
28.5 [26, 35]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Stomach</td><td align="left" rowspan="1" colspan="1">D1mL [Gy] </td><td align="left" rowspan="1" colspan="1">&#x0003c;33 Gy</td><td align="left" rowspan="1" colspan="1">
18.2 (9.7)<break/>
20 [0, 34]
</td><td align="left" rowspan="1" colspan="1">
18.7 (7.2)<break/>
20.6 [0, 31]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
19.7 (7.5)<break/>
21.6 [0, 32]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
21.3 (6.5)<break/>
22.9 [1, 33]
</td><td align="char" char="." rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D3mL [Gy] </td><td align="left" rowspan="1" colspan="1">&#x0003c;20 Gy</td><td align="left" rowspan="1" colspan="1">
15.3 (8.4)<break/>
15.2 [0, 31]
</td><td align="left" rowspan="1" colspan="1">
16.2 (6.2)<break/>
17.5 [0, 26]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
17.4 (6.7)<break/>
19.3 [0, 27]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
19.2 (6)<break/>
20.7 [1, 30]
</td><td align="char" char="." rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D9mL [Gy] </td><td align="left" rowspan="1" colspan="1">&#x0003c;15 Gy</td><td align="left" rowspan="1" colspan="1">
11.4 (6.1)<break/>
11.5 [0, 23]
</td><td align="left" rowspan="1" colspan="1">
13.1 (5.2)<break/>
14.4 [0, 19]
</td><td align="char" char="." rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">
14.2 (5.6)<break/>
15.7 [0, 20]
</td><td align="char" char="." rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">
16.4 (5.4)<break/>
17.7 [1, 23]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Dmean [Gy]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.2 (1.7) 2[0, 6]</td><td align="left" rowspan="1" colspan="1">3 (1.9) 2.8 [0, 7]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">3.4 (2.5) 3 [0, 10]</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">4.4 (2.2) 4.5 [0, 8]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Duodenum</td><td align="left" rowspan="1" colspan="1">D1mL [Gy] </td><td align="left" rowspan="1" colspan="1">&#x0003c;33 Gy</td><td align="left" rowspan="1" colspan="1">
19.8 (11.2)<break/>
19 [0, 35]
</td><td align="left" rowspan="1" colspan="1">
19.5 (9.4)<break/>
20.2 [0, 34]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
20.2 (9.1)<break/>
21.8 [0, 34]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
21.8 (9.1)<break/>
24 [0, 34]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D3mL [Gy] </td><td align="left" rowspan="1" colspan="1">&#x0003c;20 Gy</td><td align="left" rowspan="1" colspan="1">
16.9 (10.4)<break/>
15.4 [0, 33]
</td><td align="left" rowspan="1" colspan="1">
16.7 (8.3)<break/>
17.2 [0, 31]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
17.5 (8.1)<break/>
18 [0, 32]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
19.7 (8.5)<break/>
20.2 [0, 32]
</td><td align="char" char="." rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D9mL [Gy] </td><td align="left" rowspan="1" colspan="1">&#x0003c;15 Gy</td><td align="left" rowspan="1" colspan="1">
11.7 (8.8)<break/>
11.6 [0, 32]
</td><td align="left" rowspan="1" colspan="1">
12 (6.8)<break/>
13.5 [0, 26]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
12.9 (7.3)<break/>
13.9 [0, 26]
</td><td align="char" char="." rowspan="1" colspan="1">n.s. </td><td align="left" rowspan="1" colspan="1">
16.6 (7.2)<break/>
16.7 [0, 28]
</td><td align="char" char="." rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Dmean [Gy]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6.5(5.5) 5.4[0, 19]</td><td align="left" rowspan="1" colspan="1">7.2 (5.4) 6.7 [0, 22]</td><td align="char" char="." rowspan="1" colspan="1">n.s.</td><td align="left" rowspan="1" colspan="1">8 (6.1) 7.6 [0, 24]</td><td align="char" char="." rowspan="1" colspan="1">0.047</td><td align="left" rowspan="1" colspan="1">11.3(5.7)12.2[0,23]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Small bowel</td><td align="left" rowspan="1" colspan="1">D1mL [Gy] </td><td align="left" rowspan="1" colspan="1">&#x0003c;33 Gy</td><td align="left" rowspan="1" colspan="1">
17 (6)<break/>
17.6 [6, 28]
</td><td align="left" rowspan="1" colspan="1">
20.3 (5.4)<break/>
20.1 [11, 30]
</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">
21.1 (4.8)<break/>
21.6 [11, 30]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
23.6 (3.8)<break/>
24.4 [14, 29]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D3mL [Gy] </td><td align="left" rowspan="1" colspan="1">&#x0003c;20 Gy</td><td align="left" rowspan="1" colspan="1">
13.8 (5)<break/>
13.9 [3, 23]
</td><td align="left" rowspan="1" colspan="1">
17.2 (4.6)<break/>
17.9 [8, 25]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
18.1 (4.4)<break/>
19.4 [8, 25]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
20.9 (3.9)<break/>
21.9 [10, 26]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D9mL [Gy] </td><td align="left" rowspan="1" colspan="1">&#x0003c;15 Gy</td><td align="left" rowspan="1" colspan="1">
10.5 (4.3)<break/>
11.4 [2, 18]
</td><td align="left" rowspan="1" colspan="1">
13.1 (4.3)<break/>
14.3 [5, 21]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
14.1 (4.7)<break/>
15.3 [5, 22]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">
17.6 (3.9)<break/>
17.9 [6, 23]
</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Dmean [Gy]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2 (1.7) 1 [0, 7]</td><td align="left" rowspan="1" colspan="1">2.6 (2.1) 1.7 [0, 9]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2.9 (2.1) 2 [0, 9]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">4.5 (2.4) 4 [1, 9]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Lt. Kidney</td><td align="left" rowspan="1" colspan="1">V12Gy [%]</td><td align="left" rowspan="1" colspan="1">&#x0003c;75% b</td><td align="left" rowspan="1" colspan="1">0.6 (1.5) 0[0, 6]</td><td align="left" rowspan="1" colspan="1">4.1 (7.7) 0 [0, 30]</td><td align="char" char="." rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">4.3(6.7)0.4[0,22]</td><td align="char" char="." rowspan="1" colspan="1">0.008</td><td align="left" rowspan="1" colspan="1">11.4(14.1)5.2[0,52]</td><td align="char" char="." rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Rt. Kidney</td><td align="left" rowspan="1" colspan="1">V12Gy [%]</td><td align="left" rowspan="1" colspan="1">&#x0003c;75% b</td><td align="left" rowspan="1" colspan="1">3.5 (8.8) 0[0, 33]</td><td align="left" rowspan="1" colspan="1">8.6(15.9) 1.6[0, 62]</td><td align="char" char="." rowspan="1" colspan="1">0.039</td><td align="left" rowspan="1" colspan="1">10.3(18.4)1[0,67]</td><td align="char" char="." rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">13.5(10.1)13.7[0,41</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver</td><td align="left" rowspan="1" colspan="1">D50% [Gy]</td><td align="left" rowspan="1" colspan="1">&#x0003c;12 Gy</td><td align="left" rowspan="1" colspan="1">0.6 (0.5) 0[0, 2]</td><td align="left" rowspan="1" colspan="1">1.1 (0.9) 0.9[0, 3]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.2 (1) 1 [0, 3]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2.1 (1.3) 1.8 [0, 6]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Spinal Cord</td><td align="left" rowspan="1" colspan="1">V8Gy [mL]</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.3 (2.1)0 [0, 8]</td><td align="left" rowspan="1" colspan="1">2 (2.4) 0.8 [0, 7]</td><td align="char" char="." rowspan="1" colspan="1">n.s.</td><td align="left" rowspan="1" colspan="1">3.1 (3.4) 2 [0, 11]</td><td align="char" char="." rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">6.1 (4.1) 7.2 [0, 15]</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">V23Gy[mL]</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.35&#x000a0;mL</td><td align="left" rowspan="1" colspan="1">0 (0) 0 [0, 0]</td><td align="left" rowspan="1" colspan="1">0 (0) 0 [0, 0]</td><td align="char" char="." rowspan="1" colspan="1">n.s.</td><td align="left" rowspan="1" colspan="1">0 (0) 0 [0, 0]</td><td align="char" char="." rowspan="1" colspan="1">n.s.</td><td align="left" rowspan="1" colspan="1">0 (0) 0 [0, 0]</td><td align="left" rowspan="1" colspan="1">n.s.</td></tr></tbody></table><table-wrap-foot><fn id="acm212528-note-0304"><p>Abbreviations: Dxx, the dose covering xx (% or mL) of the volume; Vxx, the volume receiving xx Gy; Dmean, the mean dose; Lt., left; Rt., right; GTV, gross tumor volume; CTV, clinical target volume; CTVgeom, geometrical CTV (i.e. GTV plus 10&#x02013;15 mm margin); CTVprop, prophylactic CTV (i.e. GTV plus a prophylactic nodal areas); PTV, planning target volume; n.s., not significant.</p></fn><fn id="acm212528-note-0500"><p>All data are shown in the mean, (standard deviation), median, and [min, max] from 20 patients. PTV1, PTV2, and PTV3 are defined as a 3&#x02010;mm isotropic expansion of the GTV, CTVgeom, and CTVprop, respectively, and the overlaps between PTVs and OARs are subtracted.</p></fn><fn id="acm212528-note-0600"><p>a&#x000a0;=&#x000a0;PTV coverage was compromised if OAR constraints could not be met. b&#x000a0;=&#x000a0;combined kidney</p></fn><fn id="acm212528-note-0700"><label>*</label><p>40 Gy was prescribed to D95 of boostCTV in plan Boost2, while 33 Gy was prescribed to D95 of PTV1 in the other plans. Also, 25 Gy was prescribed to D95 of PTV2 in Boost1 and Boost2 or PTV3 in Boost3, respectively.</p></fn><fn id="acm212528-note-0800"><label>&#x02020;</label><p>
<italic>P</italic> values were calculated by paired t&#x02010;test comparing InitPlan with Boost1, Boost2, or Boost3.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Overall dose increases were observed in GI&#x02010;OARs in Boost1, Boost2, and Boost3 when compared with InitPlan (Table&#x000a0;<xref rid="acm212528-tbl-0003" ref-type="table">3</xref>). The statistical significances were distinct among three SIB&#x02010;SBRT plans. The increase in high&#x02010;dose volumes (D1&#x02013;3mL) of the stomach and duodenum was seen in Boost1 or Boost2, but was not statistically significant (displayed as &#x0201c;n.s.&#x0201d; in Table&#x000a0;<xref rid="acm212528-tbl-0003" ref-type="table">3</xref>). Although a significant increase in low&#x02010;dose volume (D9mL) of the stomach (<italic>P</italic>&#x000a0;=&#x000a0;0.032 and 0.004) and duodenum and in all DVH metrics of the small bowel were seen in both of these two SIB&#x02010;SBRT plans (all <italic>P</italic> values equal or less than 0.001), the mean DVH metrics did not exceed the dose constraints. In contrast, all DVH metrics of GI&#x02010;OARs in Boost3 significantly increased from InitPlan, and most of the mean values exceeded the dose constraints (Table&#x000a0;<xref rid="acm212528-tbl-0003" ref-type="table">3</xref>).</p><p>Among the four SBRT plans, violations were observed in 6 cases, 8 cases, 8 cases, and all 20 cases in InitPlan, Boost1, Boost2, and Boost3, respectively. All violations were observed regarding the constraints for the stomach, duodenum, or small bowels, whereas no violation was observed regarding the other OARs.</p></sec><sec id="acm212528-sec-0018"><label>3.B</label><title>Performance of DVH prediction</title><p>First, all patient data were used to develop prediction models and the predicted DVHs were analyzed. Table&#x000a0;<xref rid="acm212528-tbl-0004" ref-type="table">4</xref> and Supporting Information Fig.&#x000a0;<xref rid="acm212528-sup-0003" ref-type="supplementary-material">S3</xref> show the SRs regarding DVHs for the stomach, duodenum, and small bowel, demonstrating that all models achieved mean SR much smaller than their SDs. This implies that all models capture the essential behavior of the training set. Compared with the models in which the median value represents the doses of a distance bin (&#x0201c;Median&#x0201d; in Table&#x000a0;<xref rid="acm212528-tbl-0004" ref-type="table">4</xref>), the models in which the distribution of dose&#x02013;frequency histograms were directly used for the dose&#x02013;frequency histogram at a corresponding distance bin (&#x0201c;Distribution&#x0201d; in Table&#x000a0;<xref rid="acm212528-tbl-0004" ref-type="table">4</xref>) showed the lower mean and SDs of SRs; thus, the latter models are deemed to be the better ones.</p><table-wrap id="acm212528-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Sum of residuals between the planned and predicted dose&#x02013;volume histograms in the training cohorts</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">PLAN</th><th align="left" rowspan="2" valign="top" colspan="1">OAR<xref ref-type="fn" rid="acm212528-note-0013">b</xref>
</th><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Median<xref ref-type="fn" rid="acm212528-note-0012">a</xref>
</th><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Distribution<xref ref-type="fn" rid="acm212528-note-0012">a</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">Stomach</th><th align="center" valign="top" rowspan="1" colspan="1">Duodenum</th><th align="center" valign="top" rowspan="1" colspan="1">Bowel</th><th align="center" valign="top" rowspan="1" colspan="1">Stomach</th><th align="center" valign="top" rowspan="1" colspan="1">Duodenum</th><th align="center" valign="top" rowspan="1" colspan="1">Bowel</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">InitPlan</td><td align="left" rowspan="1" colspan="1">A</td><td align="char" char="(" rowspan="1" colspan="1">0.018 (0.023)</td><td align="char" char="(" rowspan="1" colspan="1">0.033 (0.049)</td><td align="char" char="(" rowspan="1" colspan="1">0.027 (0.036)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.022)</td><td align="char" char="(" rowspan="1" colspan="1">0.009 (0.048)</td><td align="char" char="(" rowspan="1" colspan="1">0.005 (0.033)</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="char" char="(" rowspan="1" colspan="1">0.018 (0.022)</td><td align="char" char="(" rowspan="1" colspan="1">0.012 (0.044)</td><td align="char" char="(" rowspan="1" colspan="1">0.014 (0.027)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.019)</td><td align="char" char="(" rowspan="1" colspan="1">0.006 (0.044)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.001 (0.025)</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="char" char="(" rowspan="1" colspan="1">0.009 (0.022)</td><td align="char" char="(" rowspan="1" colspan="1">0.007 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">0.008 (0.027)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.006 (0.02)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.002 (0.045)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.006 (0.026)</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="char" char="(" rowspan="1" colspan="1">0.014 (0.022)</td><td align="char" char="(" rowspan="1" colspan="1">0.015 (0.048)</td><td align="char" char="(" rowspan="1" colspan="1">0.025 (0.034)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.001 (0.02)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">0.01 (0.031)</td></tr><tr><td align="left" rowspan="4" colspan="1">Boost1</td><td align="left" rowspan="1" colspan="1">A</td><td align="char" char="(" rowspan="1" colspan="1">0.009 (0.048)</td><td align="char" char="(" rowspan="1" colspan="1">0.041 (0.095)</td><td align="char" char="(" rowspan="1" colspan="1">0.032 (0.063)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.013 (0.047)</td><td align="char" char="(" rowspan="1" colspan="1">0.016 (0.094)</td><td align="char" char="(" rowspan="1" colspan="1">0.005 (0.064)</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="char" char="(" rowspan="1" colspan="1">0.016 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">0.026 (0.098)</td><td align="char" char="(" rowspan="1" colspan="1">0.022 (0.054)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.006 (0.042)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.101)</td><td align="char" char="(" rowspan="1" colspan="1">0.006 (0.052)</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="char" char="(" rowspan="1" colspan="1">0.035 (0.046)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.097)</td><td align="char" char="(" rowspan="1" colspan="1">0.027 (0.057)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.043)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.013 (0.098)</td><td align="char" char="(" rowspan="1" colspan="1">0.005 (0.055)</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.011 (0.047)</td><td align="char" char="(" rowspan="1" colspan="1">0.035 (0.095)</td><td align="char" char="(" rowspan="1" colspan="1">0.022 (0.058)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.027 (0.044)</td><td align="char" char="(" rowspan="1" colspan="1">0.014 (0.097)</td><td align="char" char="(" rowspan="1" colspan="1">0.007 (0.056)</td></tr><tr><td align="left" rowspan="4" colspan="1">Boost2</td><td align="left" rowspan="1" colspan="1">A</td><td align="char" char="(" rowspan="1" colspan="1">0.014 (0.035)</td><td align="char" char="(" rowspan="1" colspan="1">0.061 (0.07)</td><td align="char" char="(" rowspan="1" colspan="1">0.032 (0.05)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.007 (0.033)</td><td align="char" char="(" rowspan="1" colspan="1">0.026 (0.072)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.05)</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="char" char="(" rowspan="1" colspan="1">0.018 (0.032)</td><td align="char" char="(" rowspan="1" colspan="1">0.042 (0.09)</td><td align="char" char="(" rowspan="1" colspan="1">0.01 (0.041)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.029)</td><td align="char" char="(" rowspan="1" colspan="1">0.028 (0.079)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.007 (0.042)</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="char" char="(" rowspan="1" colspan="1">0.02 (0.032)</td><td align="char" char="(" rowspan="1" colspan="1">0.018 (0.077)</td><td align="char" char="(" rowspan="1" colspan="1">0.016 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.029)</td><td align="char" char="(" rowspan="1" colspan="1">0.015 (0.075)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.004 (0.045)</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="char" char="(" rowspan="1" colspan="1">0.013 (0.033)</td><td align="char" char="(" rowspan="1" colspan="1">0.051 (0.083)</td><td align="char" char="(" rowspan="1" colspan="1">0.03 (0.049)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.002 (0.03)</td><td align="char" char="(" rowspan="1" colspan="1">0.031 (0.076)</td><td align="char" char="(" rowspan="1" colspan="1">0.011 (0.048)</td></tr><tr><td align="left" rowspan="4" colspan="1">Boost3</td><td align="left" rowspan="1" colspan="1">A</td><td align="char" char="(" rowspan="1" colspan="1">0.024 (0.052)</td><td align="char" char="(" rowspan="1" colspan="1">0.051 (0.096)</td><td align="char" char="(" rowspan="1" colspan="1">0.037 (0.054)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.051)</td><td align="char" char="(" rowspan="1" colspan="1">0.018 (0.099)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.054)</td></tr><tr><td align="left" rowspan="1" colspan="1">B</td><td align="char" char="(" rowspan="1" colspan="1">0.024 (0.048)</td><td align="char" char="(" rowspan="1" colspan="1">0.04 (0.112)</td><td align="char" char="(" rowspan="1" colspan="1">0.012 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">0.028 (0.102)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.012 (0.046)</td></tr><tr><td align="left" rowspan="1" colspan="1">C</td><td align="char" char="(" rowspan="1" colspan="1">0.034 (0.05)</td><td align="char" char="(" rowspan="1" colspan="1">0.022 (0.103)</td><td align="char" char="(" rowspan="1" colspan="1">0.021 (0.048)</td><td align="char" char="(" rowspan="1" colspan="1">0.01 (0.047)</td><td align="char" char="(" rowspan="1" colspan="1">0.014 (0.102)</td><td align="char" char=" " rowspan="1" colspan="1">&#x02212;0.005 (0.048)</td></tr><tr><td align="left" rowspan="1" colspan="1">D</td><td align="char" char="(" rowspan="1" colspan="1">0.026 (0.049)</td><td align="char" char="(" rowspan="1" colspan="1">0.059 (0.109)</td><td align="char" char="(" rowspan="1" colspan="1">0.035 (0.052)</td><td align="char" char="(" rowspan="1" colspan="1">0.007 (0.047)</td><td align="char" char="(" rowspan="1" colspan="1">0.041 (0.103)</td><td align="char" char="(" rowspan="1" colspan="1">0.012 (0.051)</td></tr></tbody></table><table-wrap-foot><fn id="acm212528-note-0011"><p>Sum of residuals (SR) are shown as mean (and standard deviation) from all 20 patients. All 20 cases are used as a single training cohort for the prediction models, and the prediction errors for actual DVHs from all 20 cases are tested.</p></fn><fn id="acm212528-note-0012"><label>a</label><p>The dose to voxels is represented by the &#x0201c;Median dose&#x0201d; or &#x0201c;Distribution&#x0201d; from dose&#x02013;frequency histograms at a corresponding distance bin.</p></fn><fn id="acm212528-note-0013"><label>b</label><p>A&#x000a0;=&#x000a0;single OAR, B&#x000a0;=&#x000a0;separated OAR with a 0&#x02010;mm interval, C&#x000a0;=&#x000a0;separated OAR with a 5&#x02010;mm interval, and D&#x000a0;=&#x000a0;separated OAR with a 10&#x02010;mm interval.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Next, half of the patient data were used for developing the model to predict DVHs in the other patients, and the double cross&#x02010;validation test was performed. Table&#x000a0;<xref rid="acm212528-tbl-0005" ref-type="table">5</xref> and Supporting Information Fig.&#x000a0;<xref rid="acm212528-sup-0004" ref-type="supplementary-material">S4</xref> show the resulting SRs of models in different settings. The mean and SDs of SRs are almost equivalent among the models, whereas the models with separate OAR volumes (Fig&#x000a0;<xref rid="acm212528-fig-0003" ref-type="fig">3</xref>, infield and outfield) and the shorter interval between PTV and the apex of the double cone had better performance than those with longer intervals according to RSS; the overall averaged RSSs from three GI&#x02010;OARs were 9.9&#x000a0;&#x000d7;&#x000a0;10e&#x02010;6 for single OAR models, and 7.9&#x000a0;&#x000d7;&#x000a0;10e&#x02010;6, 8.3&#x000a0;&#x000d7;&#x000a0;10e&#x02010;6, and 9.0&#x000a0;&#x000d7;&#x000a0;10e&#x02010;6 for separate OAR volume models with 0&#x02010;, 5&#x02010;, and 10&#x02010;mm intervals, respectively. Thus, the separate OAR volume model with the 0&#x02010;mm interval is deemed to be the best performance.</p><table-wrap id="acm212528-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Sum of residuals between the planned and predicted dose&#x02013;volume histograms</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">PLAN</th><th align="left" valign="top" rowspan="1" colspan="1">OAR<xref ref-type="fn" rid="acm212528-note-0015">a</xref>
</th><th align="center" valign="top" rowspan="1" colspan="1">Stomach</th><th align="center" valign="top" rowspan="1" colspan="1">Duodenum</th><th align="center" valign="top" rowspan="1" colspan="1">Bowel</th><th align="center" valign="top" rowspan="1" colspan="1">Lt. kidney</th><th align="center" valign="top" rowspan="1" colspan="1">Rt. kidney</th><th align="center" valign="top" rowspan="1" colspan="1">Liver</th><th align="center" valign="top" rowspan="1" colspan="1">Cord</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">InitPlan</td><td align="left" rowspan="1" colspan="1">A</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.024)</td><td align="char" char="(" rowspan="1" colspan="1">0.006 (0.052)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.034)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.004 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.05)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.025)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.024)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">B</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.021)</td><td align="char" char="(" rowspan="1" colspan="1">0.009 (0.048)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.027)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.038)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.004 (0.05)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.02)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.023)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.021)</td><td align="char" char="(" rowspan="1" colspan="1">0.009 (0.048)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.028)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.003 (0.038)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.051)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.021)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.023)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.022)</td><td align="char" char="(" rowspan="1" colspan="1">0.009 (0.049)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.032)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.003 (0.04)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.049)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.021)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.023)</td></tr><tr><td align="left" rowspan="1" colspan="1">Boost1</td><td align="left" rowspan="1" colspan="1">A</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.005 (0.051)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.105)</td><td align="char" char="(" rowspan="1" colspan="1">0.003 (0.063)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.073)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.006 (0.064)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.042)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.032)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">B</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.005 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.106)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.053)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.058)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.005 (0.061)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.031)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.03)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.005 (0.047)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.105)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.055)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.003 (0.058)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.006 (0.065)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.035)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.03)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.005 (0.047)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.005 (0.108)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.059)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.004 (0.072)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.005 (0.064)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.034)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.031)</td></tr><tr><td align="left" rowspan="1" colspan="1">Boost2</td><td align="left" rowspan="1" colspan="1">A</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.034)</td><td align="char" char="(" rowspan="1" colspan="1">0.02 (0.081)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.051)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.003 (0.074)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.068)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.042)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.028)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">B</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.03)</td><td align="char" char="(" rowspan="1" colspan="1">0.023 (0.077)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.055)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.063)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.029)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.026)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.032)</td><td align="char" char="(" rowspan="1" colspan="1">0.023 (0.078)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.047)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.004 (0.057)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.064)</td><td align="char" char="(" rowspan="1" colspan="1">0.003 (0.031)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.027)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.033)</td><td align="char" char="(" rowspan="1" colspan="1">0.025 (0.079)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.051)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.004 (0.06)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.062)</td><td align="char" char="(" rowspan="1" colspan="1">0.003 (0.031)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.027)</td></tr><tr><td align="left" rowspan="1" colspan="1">Boost3</td><td align="left" rowspan="1" colspan="1">A</td><td align="char" char="(" rowspan="1" colspan="1">0.007 (0.052)</td><td align="char" char="(" rowspan="1" colspan="1">0.019 (0.113)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.054)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.003 (0.072)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.064)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.045)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.044)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">B</td><td align="char" char="(" rowspan="1" colspan="1">0.007 (0.047)</td><td align="char" char="(" rowspan="1" colspan="1">0.024 (0.105)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.003 (0.049)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.001 (0.051)</td><td align="char" char="(" rowspan="1" colspan="1">0.002 (0.06)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.031)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.042)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C</td><td align="char" char="(" rowspan="1" colspan="1">0.007 (0.048)</td><td align="char" char="(" rowspan="1" colspan="1">0.022 (0.107)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.003 (0.051)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.003 (0.052)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.06)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.032)</td><td align="char" char="(" rowspan="1" colspan="1">0.000 (0.044)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D</td><td align="char" char="(" rowspan="1" colspan="1">0.008 (0.05)</td><td align="char" char="(" rowspan="1" colspan="1">0.024 (0.106)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.002 (0.055)</td><td align="char" char="(" rowspan="1" colspan="1">&#x02212;0.003 (0.056)</td><td align="char" char="(" rowspan="1" colspan="1">0.003 (0.059)</td><td align="char" char="(" rowspan="1" colspan="1">0.004 (0.032)</td><td align="char" char="(" rowspan="1" colspan="1">0.001 (0.042)</td></tr></tbody></table><table-wrap-foot><fn id="acm212528-note-0014"><p>Sum of residuals (SR) are shown as mean (and standard deviation) from all 20 patients. Half of 20 cases are used as a single training cohort for the prediction models, and the prediction errors for actual DVHs from the other cases are tested. This validation is repeated for 25 times and SRs are averaged out.</p></fn><fn id="acm212528-note-0015"><label>a</label><p>A&#x000a0;=&#x000a0;single OAR, B&#x000a0;=&#x000a0;separated OAR with a 0&#x02010;mm interval, C&#x000a0;=&#x000a0;separated OAR with a 5&#x02010;mm interval, and D&#x000a0;=&#x000a0;separated OAR with a 10&#x02010;mm interval.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The median absolute errors for stomach were 0.1, 1.0, and 3.3&#x000a0;mL for V33, V20, and V15, respectively. Those for duodenum were 0.0, 1.0, and 2.0&#x000a0;mL, respectively. Those for small bowel were 0.0, 1.0, and 3.1&#x000a0;mL, respectively. Supporting Information Fig.&#x000a0;<xref rid="acm212528-sup-0005" ref-type="supplementary-material">S5</xref> represents sample comparisons from two cases between the predicted DVHs and the actual DVHs from the validation set. The positive predictive value (PPV) in predicting one or more violations in critical DVH metrics (D9mL, D3mL, and D1mL) in GI&#x02010;OARs was 66% (3055/4650), and the negative predictive value (NPV) was 90% (11&#x000a0;505/12&#x000a0;750). The overall AC in predicting the valid or invalid plans was 84% (14&#x000a0;560/17&#x000a0;400), demonstrating a feasibility in identifying the plan validity. The SRs for the other OARs (kidneys, liver, and spinal cord) are also shown in Table&#x000a0;<xref rid="acm212528-tbl-0005" ref-type="table">5</xref> and Supporting Information Fig.&#x000a0;<xref rid="acm212528-sup-0004" ref-type="supplementary-material">S4</xref>. All models achieved mean SRs much smaller than their SDs. Because no violations were observed in these OARs (Table&#x000a0;<xref rid="acm212528-tbl-0003" ref-type="table">3</xref>), evaluating predictive performance of DVH metrics was avoided.</p></sec><sec id="acm212528-sec-0019"><label>3.C</label><title>Required distance&#x02010;to&#x02010;target for the prediction model</title><p>Figure&#x000a0;<xref rid="acm212528-fig-0004" ref-type="fig">4</xref> illustrates the RSSs as a function of distance&#x02010;to&#x02010;target, only within which we could use the dose histograms to develop the prediction model. As the distance&#x02010;to&#x02010;target increases, the RSS decreases in all models. The reduction of RSS was slowed over the distance of 40&#x02013;50&#x000a0;mm, suggesting that the performance of the prediction models within the distance of 40&#x02013;50&#x000a0;mm would be comparable to those with the whole (150&#x000a0;mm) distances.</p><fig fig-type="Figure" xml:lang="en" id="acm212528-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Impact of distance&#x02010;to&#x02010;target on the performance of the prediction model. The averaged sum of squared residuals (<styled-content style="fixed-case">RSS</styled-content>) between the actual and predicted dose&#x02013;volume histograms in all three gastrointestinal organs at risks from 20 patients are shown. The <styled-content style="fixed-case">RSS</styled-content>s are normalized by dividing with the <styled-content style="fixed-case">RSS</styled-content> at distance&#x02010;to&#x02010;target&#x000a0;=&#x000a0;5&#x000a0;mm (minimum).</p></caption><graphic id="nlm-graphic-7" xlink:href="ACM2-20-71-g004"/></fig></sec><sec id="acm212528-sec-0020"><label>3.D</label><title>Impact of proximity volumes of GI&#x02010;OARs on the plan validity</title><p>Supporting Information Fig <xref rid="acm212528-sup-0006" ref-type="supplementary-material">S6</xref> illustrates the median (25th&#x02013;75th percentiles) of GI&#x02010;OAR volumes from the 20 patients in the current study according to the distances from the target. We sought to evaluate the impact of the proximity volumes of GI&#x02010;OARs on the ratio of plan validity by simulations in which virtual GI&#x02010;OARs were moved and changed their positions and sizes. Figure&#x000a0;<xref rid="acm212528-fig-0005" ref-type="fig">5</xref> shows the ratio of violations of DVH metrics. Compared with the D9mL and D3mL, the violations of D1mL were not widely observed. These differences in the four plans can be intuitively appreciated because three SIB plans had larger target volume and the prescription dose to D95 of PTV2 or PTV3 was 25&#x000a0;Gy, which was far below 33&#x000a0;Gy. It is estimated that the prescription dose of 33&#x000a0;Gy for PTV1 or 40&#x000a0;Gy for boostCTV did not substantially interfere in avoiding violations of V33 even with the proximity GI&#x02010;OARs. In contrast, when proximity GI&#x02010;OAR of approximately 10&#x000a0;mL or more volumes were located within 10&#x02013;20&#x000a0;mm from the target volume, the violations for D3mL or D9mL were observed in most cases.</p><fig fig-type="Figure" xml:lang="en" id="acm212528-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Impact of proximity volumes and distances of gastrointestinal (<styled-content style="fixed-case">GI</styled-content>)&#x02010;organs at risk (<styled-content style="fixed-case">OAR</styled-content>) on plan feasibility. The probability of planning failure is estimated by simulating a virtual <styled-content style="fixed-case">GI</styled-content>&#x02010;<styled-content style="fixed-case">OAR</styled-content> to move and change its position and size. The Y axis shows the size of gastrointestinal (<styled-content style="fixed-case">GI</styled-content>)&#x02010;organs at risk (<styled-content style="fixed-case">OAR</styled-content>), and the X axis shows the range of position of <styled-content style="fixed-case">GI</styled-content>&#x02010;<styled-content style="fixed-case">OAR</styled-content>. The red color represents that the planning failure ratio is high, and blue is low. Each column represents the results of 250 situations of randomly located <styled-content style="fixed-case">GI</styled-content>&#x02010;<styled-content style="fixed-case">OAR</styled-content>.</p></caption><graphic id="nlm-graphic-9" xlink:href="ACM2-20-71-g005"/></fig></sec></sec><sec id="acm212528-sec-0021"><label>4</label><title>DISCUSSION AND CONCLUSION</title><p>Intensive efforts have been devoted for including SBRT in neoadjuvant settings of pancreatic cancer, but the prophylactic nodal irradiation has usually been avoided, and direct comparative studies of SBRT and SIB&#x02010;SBRT with prophylactic nodal areas have not yet been explored. This study is, to the best of our knowledge, the first study to focus on the detailed analysis of dosimetric feasibility of SBRT with prophylactic irradiation when administering SBRT for pancreatic cancer, in accordance with the recent dose/fractionation regimens as well as normal tissue constraints that are widely adopted in the modern clinical studies. We conducted this study for establishing the SBRT with prophylactic irradiation concept before its introduction to the clinical setting.</p><p>We performed retrospective treatment planning and comparisons of four SBRT plans to assess the planning feasibility in each SBRT scenario, and relevant questions are answered. SIB&#x02010;SBRT plans allow for inclusion of the prophylactic target volumes at the expense of dose increase to OARs. Overall, conventional SBRT (InitPlan) and experimental SIB&#x02010;SBRT with geometrical CTV (Boost1 and Boost2) satisfied all dose constraints in 63% of cases in the current study, whereas the results of including all prophylactic lymphatics (Boost3) were discouraging because no patient satisfied all dose constraints for GI&#x02010;OARs. This indicates that including a part of the prophylactic area is dosimetrically applicable, whereas the inclusion of the whole prophylactic nodal area cannot be a pragmatic approach. In addition, the inclusion of margin intensive boost yielded mostly equivalent results to Boost2, indicating that a boosting dose (40&#x000a0;Gy) to the margin of involved vasculature does not substantially increase GI&#x02010;OAR doses if the boosting area is away from GI&#x02010;OARs (1&#x000a0;cm in the current study). This result agrees with recent investigations on this strategy, opening the way for achieving a greater regression in this critical area of the tumor.<xref rid="acm212528-bib-0004" ref-type="ref">4</xref>, <xref rid="acm212528-bib-0005" ref-type="ref">5</xref>, <xref rid="acm212528-bib-0029" ref-type="ref">29</xref>
</p><p>The disappointing results of Boost3 had been expected given that the significantly larger volumes of prophylactic area (CTVprop and PTV3) yielded large overlap or proximity volumes of GI&#x02010;OARs around the target structures (Supporting Information Fig <xref rid="acm212528-sup-0006" ref-type="supplementary-material">S6</xref>). All violations were regarding dose constraints of GI&#x02010;OARs, which were confirmed to be crucial for the successful planning. Also, these violations of constraints of GI&#x02010;OARs can be attributed to intraoperative complications that we reported previously.<xref rid="acm212528-bib-0015" ref-type="ref">15</xref>, <xref rid="acm212528-bib-0016" ref-type="ref">16</xref> Based on a preliminary investigation, it was suggested that the dose coverage for the whole prophylactic nodal area needed to be relaxed at least from D95% to D90%, or 25 to 23&#x000a0;Gy or less. Also, the retropancreatic space as well as the para&#x02010;aortic region between the root of SMA and celiac trunk were supposed to be easier to cover due to an anatomical nature of GI&#x02010;OARs. However, these suggestions were not conclusive because the individual planning feasibility was highly affected by the prescription dose and the target regions (and the anatomical feature). In contrast, compared with our previous studies,<xref rid="acm212528-bib-0015" ref-type="ref">15</xref>, <xref rid="acm212528-bib-0016" ref-type="ref">16</xref> InitPlan, Boost1, and Boost2 approaches in the current study achieved the considerably lower mean doses to GI&#x02010;OARs; the mean doses to the stomach and small bowel were 3.0&#x02013;3.4&#x000a0;Gy and 2.6&#x02013;2.9&#x000a0;Gy in the current study vs 7.8 and 6.7&#x000a0;Gy in the previous study.<xref rid="acm212528-bib-0015" ref-type="ref">15</xref> This would result in an acceptable toxicity even when SIB&#x02010;SBRT concepts are used in the clinical scenario.</p><p>To elucidate how patient anatomy influenced the plan feasibility, the geometry&#x02013;dosimetry relationship was focused on in the current study. Our DVH prediction method uses the geometry&#x02013;dosimetry information in previous patients to predict DVHs based on the individual anatomy in new patients, and we demonstrated that our model has a high performance for predicting DVHs. Among previous studies of geometry&#x02010;driven DVH estimation,<xref rid="acm212528-bib-0025" ref-type="ref">25</xref>, <xref rid="acm212528-bib-0026" ref-type="ref">26</xref>, <xref rid="acm212528-bib-0027" ref-type="ref">27</xref>, <xref rid="acm212528-bib-0028" ref-type="ref">28</xref>, <xref rid="acm212528-bib-0030" ref-type="ref">30</xref> two studies investigated pancreatic SBRT: Petit et&#x000a0;al.<xref rid="acm212528-bib-0027" ref-type="ref">27</xref> used overlap volume histograms in prior patients who had an OAR that was more difficult to spare, and approximated the minimal achievable doses to liver and kidney in a new patient and identified possible candidates for replanning. More recently, Campbell et&#x000a0;al. studied the artificial neural network dose models (ANN&#x02010;DMs)<xref rid="acm212528-bib-0031" ref-type="ref">31</xref> for pancreatic SBRT using data from 43 patients, and demonstrated that the mean absolute dose errors were less than or close to 5% at all distances from PTV.<xref rid="acm212528-bib-0028" ref-type="ref">28</xref> Our results add to these evidences in that the geometry&#x02010;driven DVH prediction can be achievable to SBRT with prophylactic area irradiation using a relatively simple model suggested in the current study, and the model can secure its performance using the dose&#x02013;geometry data only within 40&#x02013;50&#x000a0;mm from the target. The unique contribution of our model is to demonstrate the predictive performance of violations of specific DVH metrics in GI&#x02010;OARs in SBRT/SIB&#x02010;SBRT plans. We also demonstrated the difficulty in achieving a valid plan when GI&#x02010;OARs had larger volume or closer distance from the target volume through simulations of random positioning of virtual GI&#x02010;OARs (Fig.&#x000a0;<xref rid="acm212528-fig-0005" ref-type="fig">5</xref>). This observation supports and can serve as a generalization of an idea of the overlapping volume between GI&#x02010;OARs and the expanded PTV and its cutoff value, which determines feasibility in achieving dose constraints as previously described by Yang et&#x000a0;al.<xref rid="acm212528-bib-0004" ref-type="ref">4</xref> The results imply that the geometry defines a large portion of planning feasibility, and strongly support a conventional recognition that the planning feasibility relies on a favorable geometry between the GI&#x02010;OARs and the target volume.</p><p>Then, important questions remain as to how SBRT or SIB&#x02010;SBRT should be offered to the cases with large proximity GI&#x02010;OARs volume. The difficulty in achieving all dose constraints in pancreatic SBRT has been recognized,<xref rid="acm212528-bib-0004" ref-type="ref">4</xref>, <xref rid="acm212528-bib-0005" ref-type="ref">5</xref> and despite the differences in the planning techniques and dose constraints, we also showed a modest successful planning ratio of 65%. This could be because of the strict dose constraints in OARs and target coverage (D95 of PTV1) as well as the importance of individual patient anatomical factors as demonstrated in the current study. To offer SBRT and SIB&#x02010;SBRT strategy to a greater patient population, pragmatic approaches currently can be applicable: (A) using an increased treatment fractionation, (B) an allowance of compromised target coverage as used in the modern clinical studies,<xref rid="acm212528-bib-0021" ref-type="ref">21</xref> and (C) separating PTV volume into subvolumes to deliver a modest dose to overlap regions with OARs or PRVs.<xref rid="acm212528-bib-0032" ref-type="ref">32</xref>, <xref rid="acm212528-bib-0033" ref-type="ref">33</xref>, <xref rid="acm212528-bib-0034" ref-type="ref">34</xref>, <xref rid="acm212528-bib-0035" ref-type="ref">35</xref> Further investigation is required for the clinical influences of the compromises in the target coverage.</p><p>We admit that there are several limitations for interpreting our results. We did not utilize volumetric modulated arc (VMAT) techniques, which were reported favorably in several studies with conventional fractionation.<xref rid="acm212528-bib-0036" ref-type="ref">36</xref>, <xref rid="acm212528-bib-0037" ref-type="ref">37</xref>, <xref rid="acm212528-bib-0038" ref-type="ref">38</xref>, <xref rid="acm212528-bib-0039" ref-type="ref">39</xref> This is because, depending on institutional policy, we had not yet started to use VMAT for pancreas SBRT in clinical practice and in a preliminary analysis we found it difficult to meet the hard constraints. We observed that VMAT tended to spread out roundly the higher isodose lines around PTVs more than IMRT, which might have resulted in failure to achieve PTV1 coverage and GI&#x02010;OAR dose constraints simultaneously. For these cases, IMRT resulted in better results. Complex target structures in the current study as well as the strict dose constraints of GI&#x02010;OARs might be reasons for the difficulty, as a previous study also reported a similar trend.<xref rid="acm212528-bib-0003" ref-type="ref">3</xref> Also, while our model was comprised relatively simple parameters and little computational burden, one possible disadvantage of our model was that it does not predict a dose at each single voxel and therefore it cannot visualize the predicted dose distribution on three&#x02010;dimensional space. Because the focuses were to evaluate the feasibility of and to elucidate geometry&#x02013;dosimetry relationship in SIB&#x02010;SBRT concepts for pancreatic cancer, the visualization of three&#x02010;dimensional point doses was abandoned in this study.</p><p>In summary, the planning feasibility of the SIB&#x02010;SBRT concept to include the a prophylactic area in pancreatic cancer was tested in this study. SBRT plans with geometrically defined CTV possibly can be treated with SIB&#x02010;SBRT techniques, but including all nodal areas with 25&#x000a0;Gy in five fractions seems unrealistic. The geometry&#x02010;driven DVH prediction model showed the strong geometry&#x02013;dosimetry relationship in pancreatic SBRT, and alternative utilization of these models was demonstrated to assess the violations based on the patient geometry. Further studies are needed to define a role of SIB&#x02010;SBRT in the clinical setting for pancreatic cancer, and future prospective studies should aim to clarify the feasibility and tolerability of SIB&#x02010;SBRT with limited prophylactic regions.</p></sec><sec id="acm212528-sec-0022"><title>CONFLICTS OF INTEREST</title><p>The authors have no relevant conflicts of interest to disclose.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="acm212528-sup-0001"><caption><p>
<bold>Fig.&#x000a0;S1.</bold> Representative dosimetry for SBRT and SIB&#x02010;SBRT plans in (a) InitPlan, (b) Boost3, (c) Boost1, and (d) Boost2. The 120% (yellow), 100% (orange), 95% (light blue), 90% (purple), 80% (blue), 70% (green), 60% (light green), and 50% (dark blue) isodose lines are depicted. The GTV is depicted as a red line. The CTVgeom is depicted as a yellow line in (c) and (d), and boostCTV is depicted as a purple line in (d). The CTVprop is depicted as an orange line in (b).</p></caption><media xlink:href="ACM2-20-71-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="acm212528-sup-0002"><caption><p>
<bold>Fig.&#x000a0;S2.</bold> Sample dose&#x02013;volume histogram (DVHs) for SBRT plan and SIB&#x02010;SBRT plans in (a) InitPlan and (b) Boost3. The DVH curves are calculated by averaging the DVHs from 20 patients in these two SBRT strategies.</p></caption><media xlink:href="ACM2-20-71-s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="acm212528-sup-0003"><caption><p>
<bold>Fig.&#x000a0;S3.</bold> Sum of residuals between the planned and predicted dose&#x02013;volume histogram (DVHs) in the training cohorts. All 20 cases are used as a single training cohort and the prediction errors from the actual DVHs are shown as absolute values. The errors are significantly lower in the &#x0201c;Distribution&#x0201d; models compared with the &#x0201c;Median&#x0201d; models.</p></caption><media xlink:href="ACM2-20-71-s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="acm212528-sup-0004"><caption><p>
<bold>Fig.&#x000a0;S4.</bold> Sum of residuals between the planned and predicted dose&#x02013;volume histograms (DVHs). Half of 20 cases are used as a single training cohort for building a prediction model and the prediction errors from the actual DVHs from the other cases are assessed. The results of errors are fluctuated between the model settings.</p></caption><media xlink:href="ACM2-20-71-s004.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="acm212528-sup-0005"><caption><p>
<bold>Fig.&#x000a0;S5.</bold> Sample dose&#x02013;volume histograms (DVHs) for three GI&#x02010;OARs from two patients (cases #11 and 14). The prediction model was generated from 10 cases (#1&#x02013;10), and the DVHs in these patients are predicted. The blue line represents the actual DVH and the yellow line represents the DVHs predicted with the geometry&#x02010;driven model.</p></caption><media xlink:href="ACM2-20-71-s005.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="acm212528-sup-0006"><caption><p>
<bold>Fig.&#x000a0;S6.</bold> Overlapping volume between GI&#x02010;OARs and the expanded target volume are shown. As the size of expanded target volume (distance&#x02010;to&#x02010;target) increases, the overlapping volume increases.</p></caption><media xlink:href="ACM2-20-71-s006.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="acm212528-bibl-0001"><title>REFERENCES</title><ref id="acm212528-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="acm212528-cit-0001">
<string-name>
<surname>Petrelli</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Comito</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ghidini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Torri</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Scorsetti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barni</surname>
<given-names>S</given-names>
</string-name>. <article-title>Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials</article-title>. <source xml:lang="en">Int J Radiat Oncol Biol Phys</source>. <year>2017</year>;<volume>97</volume>:<fpage>313</fpage>&#x02013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">28068239</pub-id></mixed-citation></ref><ref id="acm212528-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="acm212528-cit-0002">
<string-name>
<surname>Moningi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dholakia</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Raman</surname>
<given-names>SP</given-names>
</string-name>, et&#x000a0;al. <article-title>The role of stereotactic body radiation therapy for pancreatic cancer: a single&#x02010;institution experience</article-title>. <source xml:lang="en">Ann Surg Oncol</source>. <year>2015</year>;<volume>22</volume>:<fpage>2352</fpage>&#x02013;<lpage>2358</lpage>.<pub-id pub-id-type="pmid">25564157</pub-id></mixed-citation></ref><ref id="acm212528-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="acm212528-cit-0003">
<string-name>
<surname>Kumar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wild</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Ziegler</surname>
<given-names>MA</given-names>
</string-name>, et&#x000a0;al. <article-title>Stereotactic body radiation therapy planning with duodenal sparing using volumetric&#x02010;modulated arc therapy vs intensity&#x02010;modulated radiation therapy in locally advanced pancreatic cancer: a dosimetric analysis</article-title>. <source xml:lang="en">Med Dosim</source>. <year>2013</year>;<volume>38</volume>:<fpage>243</fpage>&#x02013;<lpage>250</lpage>.<pub-id pub-id-type="pmid">23540490</pub-id></mixed-citation></ref><ref id="acm212528-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="acm212528-cit-0004">
<string-name>
<surname>Yang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Reznik</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Fraass</surname>
<given-names>BA</given-names>
</string-name>, et&#x000a0;al. <article-title>Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer</article-title>. <source xml:lang="en">Med Dosim</source>. <year>2015</year>;<volume>40</volume>:<fpage>47</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">25445989</pub-id></mixed-citation></ref><ref id="acm212528-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="acm212528-cit-0005">
<string-name>
<surname>Buwenge</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cilla</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Guido</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Individually optimized stereotactic radiotherapy for pancreatic head tumors: a planning feasibility study</article-title>. <source xml:lang="en">Rep Pract Oncol Radiother</source>. <year>2016</year>;<volume>21</volume>:<fpage>548</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="pmid">27708554</pub-id></mixed-citation></ref><ref id="acm212528-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="acm212528-cit-0006">
<string-name>
<surname>Chatterjee</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Katz</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Rashid</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome</article-title>. <source xml:lang="en">Cancer</source>. <year>2012</year>;<volume>118</volume>:<fpage>3182</fpage>&#x02013;<lpage>3190</lpage>.<pub-id pub-id-type="pmid">22028089</pub-id></mixed-citation></ref><ref id="acm212528-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="acm212528-cit-0007">
<string-name>
<surname>Hirata</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Teshima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nishiyama</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses</article-title>. <source xml:lang="en">Radiother Oncol</source>. <year>2015</year>;<volume>114</volume>:<fpage>122</fpage>&#x02013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">25614389</pub-id></mixed-citation></ref><ref id="acm212528-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="acm212528-cit-0008">
<string-name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ohigashi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ishikawa</surname>
<given-names>O</given-names>
</string-name>, et&#x000a0;al. <article-title>Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine&#x02010;based chemoradiation therapy for resectable pancreatic cancer</article-title>. <source xml:lang="en">Ann Surg</source>. <year>2012</year>;<volume>255</volume>:<fpage>95</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">22123160</pub-id></mixed-citation></ref><ref id="acm212528-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="acm212528-cit-0009">
<string-name>
<surname>White</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>HB</given-names>
</string-name>, <string-name>
<surname>Gottfried</surname>
<given-names>MR</given-names>
</string-name>, et&#x000a0;al. <article-title>Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer</article-title>. <source xml:lang="en">Ann Surg Oncol</source>. <year>2005</year>;<volume>12</volume>:<fpage>214</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">15827813</pub-id></mixed-citation></ref><ref id="acm212528-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="acm212528-cit-0010">
<string-name>
<surname>Le Scodan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mornex</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Partensky</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704&#x02010;SFRO Trial</article-title>. <source xml:lang="en">Am J Clin Oncol</source>. <year>2008</year>;<volume>31</volume>:<fpage>545</fpage>&#x02013;<lpage>552</lpage>.<pub-id pub-id-type="pmid">19060585</pub-id></mixed-citation></ref><ref id="acm212528-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="acm212528-cit-0011">
<string-name>
<surname>Polistina</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Costantin</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Casamassima</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and&#x000a0;subsequent surgical exploration</article-title>. <source xml:lang="en">Ann Surg Oncol</source>. <year>2010</year>;<volume>17</volume>:<fpage>2092</fpage>&#x02013;<lpage>2101</lpage>.<pub-id pub-id-type="pmid">20224860</pub-id></mixed-citation></ref><ref id="acm212528-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="acm212528-cit-0012">
<string-name>
<surname>Chuong</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Frakes</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Figura</surname>
<given-names>N</given-names>
</string-name>, et&#x000a0;al. <article-title>Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer</article-title>. <source xml:lang="en">J Gastrointest Oncol</source>. <year>2016</year>;<volume>7</volume>:<fpage>221</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">27034789</pub-id></mixed-citation></ref><ref id="acm212528-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="acm212528-cit-0013">
<string-name>
<surname>Mellon</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Strom</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Hoffe</surname>
<given-names>SE</given-names>
</string-name>, et&#x000a0;al. <article-title>Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer</article-title>. <source xml:lang="en">J Gastrointest Oncol</source>. <year>2016</year>;<volume>7</volume>:<fpage>547</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">27563444</pub-id></mixed-citation></ref><ref id="acm212528-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="acm212528-cit-0014">
<string-name>
<surname>Hong</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Blaszkowsky</surname>
<given-names>LS</given-names>
</string-name>, et&#x000a0;al. <article-title>Phase I study of preoperative short&#x02010;course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head</article-title>. <source xml:lang="en">Int J Radiat Oncol Biol Phys</source>. <year>2011</year>;<volume>79</volume>:<fpage>151</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">20421151</pub-id></mixed-citation></ref><ref id="acm212528-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="acm212528-cit-0015">
<string-name>
<surname>Wo</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Mamon</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Ferrone</surname>
<given-names>CR</given-names>
</string-name>, et&#x000a0;al. <article-title>Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer</article-title>. <source xml:lang="en">Radiother Oncol</source>. <year>2014</year>;<volume>110</volume>:<fpage>160</fpage>&#x02013;<lpage>164</lpage>.<pub-id pub-id-type="pmid">24231241</pub-id></mixed-citation></ref><ref id="acm212528-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="acm212528-cit-0016">
<string-name>
<surname>Kozak</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Kachnic</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment</article-title>. <source xml:lang="en">Int J Radiat Oncol Biol Phys</source>. <year>2007</year>;<volume>68</volume>:<fpage>1557</fpage>&#x02013;<lpage>1566</lpage>.<pub-id pub-id-type="pmid">17544599</pub-id></mixed-citation></ref><ref id="acm212528-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="acm212528-cit-0017">
<string-name>
<surname>Robertson</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>S&#x000f6;hn</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>D</given-names>
</string-name>. <article-title>Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff&#x02010;dose logistic regression normal tissue complication probability model</article-title>. <source xml:lang="en">Int J Radiat Oncol Biol Phys</source>. <year>2010</year>;<volume>77</volume>:<fpage>66</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">19665323</pub-id></mixed-citation></ref><ref id="acm212528-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="acm212528-cit-0018">
<string-name>
<surname>Murphy</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Christman&#x02010;Skieller</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dieterich</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Koong</surname>
<given-names>AC</given-names>
</string-name>. <article-title>A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer</article-title>. <source xml:lang="en">Int J Radiat Oncol Biol Phys</source>. <year>2010</year>;<volume>78</volume>:<fpage>1420</fpage>&#x02013;<lpage>1426</lpage>.<pub-id pub-id-type="pmid">20399033</pub-id></mixed-citation></ref><ref id="acm212528-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="acm212528-cit-0019">
<string-name>
<surname>Goldsmith</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Price</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cross</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Loughlin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cowley</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Plowman</surname>
<given-names>N</given-names>
</string-name>. <article-title>Dose&#x02010;volume histogram analysis of stereotactic body radiotherapy treatment of pancreatic cancer: a focus on duodenal dose constraints</article-title>. <source xml:lang="en">Semin Radiat Oncol</source>. <year>2016</year>;<volume>26</volume>:<fpage>149</fpage>&#x02013;<lpage>156</lpage>.<pub-id pub-id-type="pmid">27000512</pub-id></mixed-citation></ref><ref id="acm212528-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="acm212528-cit-0020">
<string-name>
<surname>Bae</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>CK</given-names>
</string-name>, et&#x000a0;al. <article-title>Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies</article-title>. <source xml:lang="en">Int J Radiat Oncol Biol Phys</source>. <year>2012</year>;<volume>84</volume>:<fpage>e469</fpage>&#x02013;<lpage>e474</lpage>.<pub-id pub-id-type="pmid">23078899</pub-id></mixed-citation></ref><ref id="acm212528-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="acm212528-cit-0021">
<string-name>
<surname>Herman</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>
<given-names>KA</given-names>
</string-name>, et&#x000a0;al. <article-title>Phase 2 multi&#x02010;institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma</article-title>. <source xml:lang="en">Cancer</source>. <year>2015</year>;<volume>121</volume>:<fpage>1128</fpage>&#x02013;<lpage>1137</lpage>.<pub-id pub-id-type="pmid">25538019</pub-id></mixed-citation></ref><ref id="acm212528-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="acm212528-cit-0022">
<string-name>
<surname>Benedict</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Yenice</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Followill</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Stereotactic body radiation therapy: the report of AAPM Task Group 101</article-title>. <source xml:lang="en">Med Phys</source>. <year>2010</year>;<volume>37</volume>:<fpage>4078</fpage>&#x02013;<lpage>4101</lpage>.<pub-id pub-id-type="pmid">20879569</pub-id></mixed-citation></ref><ref id="acm212528-bib-0023"><label>23</label><mixed-citation publication-type="miscellaneous" id="acm212528-cit-0023">
<article-title>National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 3</article-title>; <year>2017</year>.</mixed-citation></ref><ref id="acm212528-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="acm212528-cit-0024">
<string-name>
<surname>Arvold</surname>
<given-names>ND</given-names>
</string-name>, <string-name>
<surname>Niemierko</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mamon</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x02010;del Castillo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>TS</given-names>
</string-name>. <article-title>Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning</article-title>. <source xml:lang="en">Int J Radiat Oncol Biol Phys</source>. <year>2011</year>;<volume>80</volume>:<fpage>1383</fpage>&#x02013;<lpage>1390</lpage>.<pub-id pub-id-type="pmid">20708856</pub-id></mixed-citation></ref><ref id="acm212528-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="acm212528-cit-0025">
<string-name>
<surname>Appenzoller</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Michalski</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Thorstad</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Mutic</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>KL</given-names>
</string-name>. <article-title>Predicting dose&#x02010;volume histograms for organs&#x02010;at&#x02010;risk in IMRT planning</article-title>. <source xml:lang="en">Med Phys</source>. <year>2012</year>;<volume>39</volume>:<fpage>7446</fpage>&#x02013;<lpage>7461</lpage>.<pub-id pub-id-type="pmid">23231294</pub-id></mixed-citation></ref><ref id="acm212528-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="acm212528-cit-0026">
<string-name>
<surname>Tran</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Woods</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Predicting liver SBRT eligibility and plan quality for VMAT and 4<italic>&#x003c0;</italic> plans</article-title>. <source xml:lang="en">Radiat Oncol</source>. <year>2017</year>;<volume>12</volume>:<fpage>70</fpage>.<pub-id pub-id-type="pmid">28438215</pub-id></mixed-citation></ref><ref id="acm212528-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="acm212528-cit-0027">
<string-name>
<surname>Petit</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kazhdan</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Increased organ sparing using shape&#x02010;based treatment plan optimization for intensity modulated radiation therapy of pancreatic adenocarcinoma</article-title>. <source xml:lang="en">Radiother Oncol</source>. <year>2012</year>;<volume>102</volume>:<fpage>38</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">21680036</pub-id></mixed-citation></ref><ref id="acm212528-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="acm212528-cit-0028">
<string-name>
<surname>Campbell</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Miften</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Olsen</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Neural network dose models for knowledge&#x02010;based planning in pancreatic SBRT</article-title>. <source xml:lang="en">Med Phys</source>. <year>2017</year>;<volume>44</volume>:<fpage>6148</fpage>&#x02013;<lpage>6158</lpage>.<pub-id pub-id-type="pmid">28994459</pub-id></mixed-citation></ref><ref id="acm212528-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="acm212528-cit-0029">
<string-name>
<surname>Holyoake</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Grose</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Conformity analysis to demonstrate reproducibility of target volumes for margin&#x02010;intense stereotactic radiotherapy for borderline&#x02010;resectable pancreatic cancer</article-title>. <source xml:lang="en">Radiother Oncol</source>. <year>2016</year>;<volume>121</volume>:<fpage>86</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">27519585</pub-id></mixed-citation></ref><ref id="acm212528-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="acm212528-cit-0030">
<string-name>
<surname>Wu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ricchetti</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Sanguineti</surname>
<given-names>G</given-names>
</string-name>, et&#x000a0;al. <article-title>Patient geometry&#x02010;driven information retrieval for IMRT treatment plan quality control</article-title>. <source xml:lang="en">Med Phys</source>. <year>2009</year>;<volume>36</volume>:<fpage>5497</fpage>&#x02013;<lpage>5505</lpage>.<pub-id pub-id-type="pmid">20095262</pub-id></mixed-citation></ref><ref id="acm212528-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="acm212528-cit-0031">
<string-name>
<surname>Shiraishi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>KL</given-names>
</string-name>. <article-title>Knowledge&#x02010;based prediction of three&#x02010;dimensional dose distributions for external beam radiotherapy</article-title>. <source xml:lang="en">Med Phys</source>. <year>2016</year>;<volume>43</volume>:<fpage>378</fpage>.<pub-id pub-id-type="pmid">26745931</pub-id></mixed-citation></ref><ref id="acm212528-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="acm212528-cit-0032">
<string-name>
<surname>Brunner</surname>
<given-names>TB</given-names>
</string-name>, <string-name>
<surname>Nestle</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Adebahr</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Simultaneous integrated protection: a new concept for high&#x02010;precision radiation therapy</article-title>. <source xml:lang="en">Strahlenther Onkol</source>. <year>2016</year>;<volume>192</volume>:<fpage>886</fpage>&#x02013;<lpage>894</lpage>.<pub-id pub-id-type="pmid">27757502</pub-id></mixed-citation></ref><ref id="acm212528-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="acm212528-cit-0033">
<string-name>
<surname>Nakamura</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shibuya</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Interfractional dose variations in the stomach and the bowels during breathhold intensity&#x02010;modulated radiotherapy for pancreatic cancer: implications for a dose&#x02010;escalation strategy</article-title>. <source xml:lang="en">Med Phys</source>. <year>2013</year>;<volume>40</volume>:<fpage>021701</fpage>.<pub-id pub-id-type="pmid">23387724</pub-id></mixed-citation></ref><ref id="acm212528-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="acm212528-cit-0034">
<string-name>
<surname>Gkika</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Adebahr</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kirste</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer: a toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT</article-title>. <source xml:lang="en">Strahlenther Onkol</source>. <year>2017</year>;<volume>193</volume>:<fpage>433</fpage>&#x02013;<lpage>443</lpage>.<pub-id pub-id-type="pmid">28138949</pub-id></mixed-citation></ref><ref id="acm212528-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="acm212528-cit-0035">
<collab collab-type="authors">International Commission on Radiation Units and Measurements</collab>
. <article-title>ICRU Report 83: prescribing, recording, and reporting photon beam intensity modulated radiation therapy (IMRT)</article-title>. <source xml:lang="en">J ICRU</source>. <year>2010</year>;<volume>10</volume>.</mixed-citation></ref><ref id="acm212528-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="acm212528-cit-0036">
<string-name>
<surname>Cai</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yue</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McLawhorn</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Dosimetric comparison of 6 MV and 15 MV single arc rapidarc to helical TomoTherapy for the treatment of pancreatic cancer</article-title>. <source xml:lang="en">Med Dosim</source>. <year>2011</year>;<volume>36</volume>:<fpage>317</fpage>&#x02013;<lpage>320</lpage>.<pub-id pub-id-type="pmid">20846850</pub-id></mixed-citation></ref><ref id="acm212528-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="acm212528-cit-0037">
<string-name>
<surname>Vieillot</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Azria</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Riou</surname>
<given-names>O</given-names>
</string-name>, et&#x000a0;al. <article-title>Bilateral kidney preservation by volumetric&#x02010;modulated arc therapy (RapidArc) compared to conventional radiation therapy (3D&#x02010;CRT) in pancreatic and bile duct malignancies</article-title>. <source xml:lang="en">Radiat Oncol</source>. <year>2011</year>;<volume>6</volume>:<fpage>147</fpage>.<pub-id pub-id-type="pmid">22040762</pub-id></mixed-citation></ref><ref id="acm212528-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="acm212528-cit-0038">
<string-name>
<surname>Ali</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Dhabaan</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Jarrio</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Siddiqi</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Landry</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Dosimetric comparison of volumetric modulated arc therapy and intensity&#x02010;modulated radiation therapy for pancreatic malignancies</article-title>. <source xml:lang="en">Med Dosim</source>. <year>2012</year>;<volume>37</volume>:<fpage>271</fpage>&#x02013;<lpage>275</lpage>.<pub-id pub-id-type="pmid">22189026</pub-id></mixed-citation></ref><ref id="acm212528-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="acm212528-cit-0039">
<string-name>
<surname>Chapman</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Witek</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Showalter</surname>
<given-names>TN</given-names>
</string-name>, <string-name>
<surname>Bar&#x02010;Ad</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Harrison</surname>
<given-names>AS</given-names>
</string-name>. <article-title>Pancreatic cancer planning: complex conformal vs modulated therapies</article-title>. <source xml:lang="en">Med Dosim</source>. <year>2016</year>;<volume>41</volume>:<fpage>100</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">26831922</pub-id></mixed-citation></ref></ref-list></back></article>